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Abstract 
Background: Lung function declines with old age and is further accelerated by 
exposure to noxious particles. As our society ages, expected lifespan increases, and 
prevalence of chronic obstructive pulmonary disease (COPD) is on the rise. 
Spirometry is used both to diagnose and to grade the degree of airway obstruction, 
but many elderly fail to perform this procedure satisfactory. More tools are needed to 
evaluate this large patient group. The present study explores the use of forced 
oscillation technique (FOT) in healthy elderly and in a longitudinal case-control study 
of COPD patients and controls.  
Aims: 
• Generate reference values for FOT using impulse oscillations in healthy 
elderly.  
• Evaluate the agreement between two methods: sinusoidal pressure oscillations 
and impulse oscillations.  
• Evaluate variability of whole-breath and within-breath FOT measurements, 
examine factors influencing tidal expiratory flow limitation, and describe its 
impact on morbidity and mortality.  
Materials and Methods: regional ethics committees have approved all studies. In the 
first study, predictive equations were generated for FOT parameters in 75 subjects 
with normal spirometry who were drawn in an age and sex stratified sample from 
healthy, non-smoking responders of a health questionnaire in elderly, aged >70 years. 
The second study examined the agreement between sinusoidal pressure oscillations 
and impulse oscillations in 20 patients in a rehabilitation hospital. The final study 
followed 425 COPD and 229 controls over 3 years/8 visits with FOT and spirometry. 
Six-minute walk distance (6MWD) was assessed at baseline and at the final visit, 
respiratory symptoms, exacerbations, and hospitalizations were recorded, and 
mortality statistics retrieved retrospectively.  
 
 
   
ix
Results: Reference values for whole-breath and within-breath FOT parameters were 
generated in healthy elderly. In non flow-limited patients, good agreement between 
sinusoidal and impulse pressure oscillations was found. Flow-limited patients had 
higher variability than the expected biological variability and significantly higher 
resistance values. Healthy controls had little variability in the FOT measurements. A 
higher variability was found in COPD patients. COPD patients with mean within-
breath reactance, ∆ >0.1 kPa·s·L-1 were more breathless. The upper limit of 
normal (ULN), defined at the 97.5 percentile of ∆, in healthy controls was 0.09 
kPa·s·L-1. COPD patients with ∆ ≥ULN had a significant decline in 6MWD from 
baseline to the final visit, more exacerbations and more hospitalizations than COPD 
patients with ∆ in the normal range. COPD patients with FEV1 >50% and ∆ 
≥ULN also had a significantly higher mortality. 
Conclusions: Reference equations generated in healthy elderly yielded higher 
resistance measurements than what was found when simply extrapolating existing 
reference equations generated in a younger population. When examining agreement 
between sinusoidal pressure oscillations and impulse oscillations, impulse oscillations 
overestimated resistance in patients with flow-limitation. We describe a new method 
to assess flow-limitation in COPD patients by averaging measurements over several 
breaths. The COPD patients with ∆ >0.1 kPa·s·L-1, just above the ULN were more 
likely to report dyspnea. ∆ ≥ULN in COPD was associated with a significant 
decline in 6MWD, more moderate and severe exacerbations, and in patients with 
moderate airway obstruction, a significantly higher mortality.  
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“Life and respiration are complimentary. There is nothing living which does not 
breathe nor anything breathing which does not live.” 
William Harvey (1653) 
Measuring of breath by spirometry is the most common pulmonary function test. 
We use it to diagnose obstructive pulmonary disease. We use it to track disease 
progression, and we use it to measure the effect of a given treatment [1, 2]. 
Additionally, when lung volumes decline, they are not only markers of 
pulmonary disease, but also some of our most powerful predictors of 
cardiovascular disease and death [3, 4]. Simply put, in pulmonary medicine, 
spirometry is the most important test. Even so, it is not without limitations.  
Spirometry depends highly on cooperation and on the effort involved, and an 
adequate spirometry procedure may be difficult to obtain in some patients [5, 6]. 
Spirometry alone does not capture dynamic changes occurring during tidal 
volume breathing, such as the changes in end-expiratory lung volume seen in 
patients with dynamic hyperinflation, and spirometry cannot be used to detect 
flow limitation during tidal volume breathing. These are only some of the reasons 
why alternative ways to evaluate lung function, requiring less patient 
cooperation, are needed. 
The following study explores a new method to evaluate lung function in healthy 
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1.1 The aging population 
Since the mid-twentieth century an unprecedented aging of the world population 
has occurred, driven not only by a decrease in child mortality, but also by 
considerable increase in longevity. Globally, the number of elderly aged 60 years 
and older is expected to more than double by 2050 to an estimated 2 billion 
people [7].  
A similar trend is seen in Norway where our elderly population >70 years is 
projected to double within the next 30 years, and our proportion of elderly to 
increase from today’s 11% to 19% of the total population by 2060 [8]. 
This reshaping of the population brings challenges to clinical and 
epidemiological research. As disability, co-morbidities, and multiple-medication 
increase with age, healthy norm populations used as reference are increasingly 
difficult to recruit. At the same time, the number of volunteers in elderly 
populations is often small, and further diminishes when the asymptomatic 
individuals without pre-existing conditions are identified. 
All the same, elderly are overrepresented in our hospital wards, particularly in the 
departments of thoracic medicine. According to Statistics Norway, 54% of the 
20.916 patients admitted to hospital in 2016 with the diagnose of chronic 
obstructive pulmonary disease (COPD) were aged 70 years and older, 
highlighting the importance of reliable reference studies in elderly [9].  
1.2 Pulmonary function in the elderly 
Aging brings visible changes. Our skin becomes lined and less elastic and 
wrinkles appear. Height is often reduced, and postural changes may influence the 
movement of our rib cage. Similar changes affect our internal organs. The most 
prominent physiological change to our lungs, is the loss of elastic recoil caused 
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by decrease and alteration in the cross-linkage of elastic fibers and collagen [10]. 
Skeletal changes such as osteoarthritis of the costovertebral junctions and 
calcification of the sternocostal joints, increase the stiffness of the chest wall and 
leads to increased rigidity [11]. Kyphosis may reduce the maximal lung volume. 
The pulmonary vasculature also becomes stiffer, and the pulmonary arterial 
pressure increases [12, 13]. Even healthy aging brings enlargement of the 
alveolar airspaces and reduction in the total number of alveoli, leading to a 
reduced surface area for gas diffusion [14-16]. Consequently, pulmonary gas 
exchange declines with age [17]. In addition, weakening of respiratory muscle 
strength due to atrophy, and age related decrease in type II, fast twitch fibers, 
may aggravate the effect of these morphological changes on breathing [18]. 
As a consequence, decrease in lung function with age is expected. This is 
reflected in our reference equations for spirometry [19, 20]. Inhaled particles, 
particularly those of cigarette smoke accelerate this decline. In a hallmark study 
by Fletcher and Peto the natural decline in lung function and the accelerated 
decline associated with smoking was illustrated, Figure 1 [21]. 
 
Figure 1. The Fletcher and Peto’s curve illustrates the natural decline in Forced Expiratory Volume in 1 
second (FEV1) [21].  Reproduced with permission from BMJ Publishing Group Ltd. 
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1.3 Chronic Obstructive Pulmonary Disease 
The 2017 update of the Global Initiative for Chronic Obstructive Lung Disease 
report defines COPD as follows:  
“Chronic Obstructive Pulmonary Disease (COPD), a common preventable and 
treatable disease, is characterized by persistent airflow limitation that is usually 
progressive and associated with an enhanced chronic inflammatory response in the 
airways and the lung to noxious particles or gases. Exacerbations and comorbidities 
contribute to the overall severity in individual patients.”[1] 
In spite of the trend towards longer, healthier lives, a longer life expectancy also 
expands our lifetime exposure to risk factors, and chronic degenerative diseases 
becomes more common[1, 7]. We have seen considerable reduction in daily 
smokers in most western countries [22]. A 50% reduction in daily smokers has 
been noted in Norway since the 1980s [22]. Still, the smoking epidemic of the 
20th century left a heavy burden, and we may not have reached the peak 
prevalence of COPD yet. COPD was rated the 3rd leading cause of death in 2012, 
with an estimated 3 million deaths worldwide. In Norway the prevalence is 
estimated at 14% of the adult population, or approximately 400.000 people. Only 
a fraction has been diagnosed [23]. As our population ages, we expect the 
number of people living with COPD to rise. While spirometry is used to diagnose 
and to grade the degree of airway obstruction, the ability to perform spirometry 
satisfactory falls with age [6, 24, 25]. New tools to help assess this huge patient 
group, are welcomed 
1.4 Spirometry 
Spirometry assesses lung function by measuring the amount of air a test subject 
can exhale after a maximal inhalation [26]. While some measurements can be 
retrieved unforced, the most common procedure is the forced expiration 
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maneuver. Key parameters are the forced expiration in 1 second (FEV1) and the 
forced vital capacity (FVC). The measurement depends on the test subject 
blowing the air out as fast and forcibly as possible and that he or she continues to 
do so until the lungs are fully emptied (to the residual volume). FEV1 is the 
volume of air exhaled in the first second of the blow. In COPD FEV1 is used to 
assess the severity of the airflow obstruction by comparing the measured 
volumes against a reference value based on age, height, sex, and ethnicity [1]. 
Forced vital capacity (FVC) is the total volume of air that forcibly can be expired 
in one breath. The fraction of air expelled in the first second relative to the total 
volume exhaled, the FEV1/FVC ratio is used to confirm presence of airway 
obstruction. This ratio is independent of ethnicity, which allows for a universal 
definition of airway obstruction [20]. In COPD the fixed ratio of 0.7 is 
recommended to verify the presence of airway obstruction [1]. Due to a natural 
decline in the FEV1/FVC ratio with age, this may lead to an overestimation of 
airway obstruction in the elderly [27]. Alternately, the lower limit of normal 
(LLN) can be used, classifying the lower 5% as abnormal to reduce 
misclassification of airway obstruction in the elderly [1, 20].  
1.5 Forced oscillation technique 
Recent discoveries using forced oscillation technique (FOT) show promise in the 
evaluation of COPD patients. FOT detects early respiratory changes due to 
smoking [28]. In addition FOT accurately detects tidal expiratory flow limitation 
(EFLT), and a high correlation between improvement in symptoms and changes 
in certain FOT parameters have been found during resolution of COPD 
exacerbations [29-31].  
FOT superimposes sound waves from a loudspeaker to spontaneous breathing. 
The pulmonary impedance (Zrs) is then calculated from the resultant 
pressure/flow signals measured at the mouthpiece. Zrs describes the total 
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mechanical load of the respiratory system and is further subdivided into 
resistance (Rrs) describing the frictional forces on the airflow moving through 
airways, and reactance (Xrs) reflecting storage and release of energy cause by the 
elasticity of the tissue. Their relation is expressed in Equation 1 [32]:  
 
Equation 1.     =    
 
The first attempts to measure lung function using forced oscillations were made 
already in the 1950s [33]. At that time calculations had to be performed by hand, 
and only single frequency sinusoidal pressure signals were used in order to 
simplify calculations. It took decades before advances in microprocessor 
technology made commercial apparatuses available. Today oscillatory forcing 
signals can be either mono- or multi-frequency, applied continuously or as a train 
of impulses.  
In the following studies we used impulse oscillations to measure oscillatory lung 
mechanics [34-37]. FOT measures airway mechanics non-invasively during 
resting breathing. It is effort independent and does not requiring complex 
breathing manoeuvres. In elderly higher feasibility have been found for FOT than 
for spirometry [6, 24].  
1.6 Reference values for whole-breath and within 
breath FOT parameters 
When we started this study, reference values for oscillation mechanics in adults 
were limited, and the number of elderly participating in these studies low, Table 
1 [32, 35, 38-46]. Although respiratory impedance is age dependent, only one 
reference study reported reference values in elderly using continuous 
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pseudorandom noise (PRN) [41]. However, one report has documented 
systematic differences in resistance measurements between devices using 
different forcing signals, a continuous PRN device and an impulse oscillation 
system (IOS) [47]. This finding calls for verification. If different forcing signals 
yield different results, device specific reference values are needed. 
For the IOS, the software reports normal values based on unpublished reference 
equations generated from 506 healthy subjects in Erfurd, Germany aged 18-69 
[32]. If older patient are tested, the software extrapolates normal values from 
these equations, generated from a younger population. Japanese and Australian 
normal values had also been published. Both studies contained few elderly [44, 
46].  
Respiratory impedance measurements vary within the breathing cycle. Resistance 
(Rrs) measurements are higher during expiration than in the inspiratory phase 
[48-54]. The variability of the measurements is lower in inspiration than 
expiration, and in patients with COPD, the differences between inspiration and 
expiration is larger than in healthy subjects [49]. Reactance (Xrs) decreases in 
expiration both in healthy subjects and in patients with COPD with the largest 
difference in the COPD patients [30, 49, 51, 53]. Similar changes have also been 
reported for other FOT parameters, such as the resonant frequency and the area 
of reactance [49].  
Pulmonary impedance (Zrs) changes in the respiratory cycle have been studied in 
a wide range of conditions, including patients on mechanical ventilation [55-59], 
while using nasal CPAP [60], in sleep studies [61, 62], in patients with interstitial 
lung disease [63], and in patients with obstructive lung disease [29-31, 64]. 
Normal values for within-breath impedance parameters would make 
interpretation easier. We have only found 1 study reporting within-breath 
reference equations for FOT [42]. This study reported reference equations for 
men and women, calculating inspiratory and expiratory Rrs based on the end-
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expiratory thoracic gas volume. Due to small sample size (n=65), and the use of 
only one predictor, these equations have limited precision. Reference equations 
are also easier to use if based on demographic data rather than a 
plethysmographic parameter like the end-expiratory thoracic gas volume. Normal 
values for other within-breath impedance measurements have yet to be published.  
These are some of the reasons why device specific reference values for IOS in 
elderly are needed. Existing reference values for within-breath FOT parameters 
are incomplete, only reporting respiratory Rrs. In addition, more studies are 
needed comparing different devices.  
Table 1. Reference values for forced oscillation technique (FOT) in adults 
     Age  
Study Year Participants Signal Men Mean Range N 
Jiemsripong [42] 1976 Healthy subjects, USA SIN 47 % 40 21-64 76 
Landsér [43] 1982 Healthy subjects, Belgian Air 
Force 
PRN 100% 26 15-57 224 
Clemént [65] 1983 Healthy subjects, Belgian Air 
Force 
PRN 100% 29 15-57 442 
Vogel [32] 1994 Healthy subjects, Germany IOS 59 %  18-69 506 
Goevarts 24 1994 Healthy subjects PRN  51  60 
Pasker [45] 1996 Healthy subjects, Belgium PRN 49 % 56 21-83 277 
Guo [41] 2005 Lunge healthy inpatients, 
Switzerland 
PRN 35 % 83 65-100 223 
Shiota [46] 2005 Healthy subjects, Japan IOS 60 % 39 20-83 299 
Newbury 2008 Healthy subjects, Australia IOS 47 % 49 25-74 125 
Brown [38] 2010 Healthy subjects, Australia PRN 38 % 55 18-92 904 
Aarli [35] 2013 Healthy elderly, Norway IOS 53 % 79 70-98 75 
Schulz [66] 2013 Never smoking lung healthy, 
Germany 
IOS 39 %  45-89 397 
Year: year of publication. SIN: Sinusoidal pressure oscillations. PRN: Pseudo random noise. IOS: impulse 
oscillations. N: number of subjects. 
 
1.7 Tidal expiratory flow limitation 
Chronic airway obstruction is a diagnostic criterion in COPD, defined when 
repeatedly, no more 70% of the vital capacity can be exhaled within the first 
second of a forced expiration manoeuvre [67]. At advanced disease, flow 
limitation often presents at exercise, and frequently even when sitting still, 
breathing at rest [68-70]. When this occurs and maximal flow is reached at tidal 
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volume breathing, tidal expiratory flow limitation, EFLT is said to be present 
[71].  
At extreme exercise, the mechanical limits of breathing may even cause 
expiratory flow limitation during in healthy subjects [72]. As demands for 
ventilation increase during progressive exercise, this is achieved either by 
increasing the tidal volume or the respiratory rate. The tidal volume is increased 
by encroaching both on the inspiratory and the expiratory reserve volumes, 
Figure 2 [73].  
 
Figure 2. Lung volumes. The image shows 4 tidal volume breaths, which is the volume of air inhaled in a 
single breath, followed by a maximal inspiration reaching the total lung capacity (TLC) and a maximal 
expiration reaching the residual volume. The inspiratory capacity is the volume from TLC to the end-
expiratory lung volume. 
In healthy lungs, the lung volume at relaxed end-expiration lung volume is 
determined by the balancing forces between the outward recoil pressure of the 
chest wall and the inward elastic pressure of the lungs [74]. During maximal 
exercise, end-expiratory lung volume (EELV) may decrease to the point where 
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at low lung volumes. To avoid expiratory flow limitation, EELV is increased at 
high intensity exercise, and further increases in tidal volumes are derived from 
the inspiratory reserve volume alone. At the same time, the time for lung 
emptying at this flow rate may be insufficient for the lungs to reach their normal 
relaxation EELV, resulting in an increasing degree of air-trapping. This has been 
termed dynamic hyperinflation, Figure 3. With loss of the elastic recoil in lungs 
in elderly and in patients with COPD, residual volume and closing capacity are at 
higher lung volumes then in younger subjects [10]. These effects reduce the 
ranges of the operating lung volumes. Dynamic hyperinflation occurs at lower 
intensity exercise in elderly and in patients with COPD than in younger healthy 
subjects, and patients with COPD commonly resort to a static hyperinflation, 
breathing at higher lung volumes then healthy subjects already at rest in order to 
avoid EFLT. 
 
Figure 3. Changes in tidal volume loops from rest to exercise. A) In a healthy subject inspiratory capacity 
(IC). In COPD patients the end-expiratory lung volume frequently shifts to the left due to insufficient 
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1.8 Methods for EFLT detection 
Direct assessment of EFLT requires the demonstration that an increase in the 
transpulmonary pressure fails to increase expiratory flow. Measuring 
transpulmonary pressure directly in the pleura is impractical and involves the risk 
of pneumothorax. For this reason the intrathoracic pressure measured in the 
esophagus is used as a substitute. The esophageal pressure is representative for 
the intrapleural pressure and can be measured by inserting a catheter through the 
mouth or nose with an air filled, thin walled balloon [75]. The Mead and 
Whittenberger method to detect EFLT estimates the transpulmonary pressure 
using an esophageal balloon while measuring flow in a body box [76]. Figure 4 
shows the flow-pressure relationship in a non-flow limited patients and in a 
patient with EFLT measured with the Mead and Whittenberger method. 
Drawbacks of this technique are that it is invasive, technically complex, and 
relatively time consuming.  
 
Figure 4. Mead and Whittenberger graphs plotting flow measured at the airway opening plotted against 
the pressure drop during a tidal volume breath in a COPD patient without flow limitation (A) and in a 
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A non-invasive method to detect EFLT was proposed by Hyatt in 1961 by 
superimposing a tidal breath flow-volume curve on a maximal expiratory flow 
volume (MEFV) curve [77]. By this technique, EFLT is defined to be present if 
the flow-volume trace of a tidal volume breath is along or higher than the MEFV, 
and not present if the breath is below the MEFV curve, Figure 5. The technique 
requires volume to be measured in a body box in order to avoid gas compression 
artifacts and patient cooperation is necessary to produce the MEFV curves. 
Aligning and comparing the flow-volume curves correctly may be difficult [78, 
79]. 
           
Figure 5. Tidal volume flow-volume curve superimposed on a maximal expiratory flow volume curve in a 
patient with no EFLT (A) and in a patient with EFLT (B) 
The negative expiratory pressure (NEP) technique simplifies EFLT detection by 
not requiring patient cooperation, FVC maneuvers, or use of a body box [80]. 
When a negative pressure is applied to the breathing circuit at the beginning of 
expiration, either by a vacuum cleaner or a venturi device, the increased pressure 
gradient between the airway opening and the alveoli leads to an increase in flow 
unless the test subject already is breathing at maximal flow at tidal volume 
breathing. When EFLT is present, NEP fails to increase the flow, Figure 6. EFLT 
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Figure 6. Tidal volume flow-volume curves during the negative expiratory pressure (NEP) technique.  In 
COPD patients without EFLT, NEP induces an increased flow (A). In EFLT COPD patients the NEP fails 
to increase flow compared with the previous tidal volume curve (B).  
 
EFLT may also be detected by FOT. When EFLT occurs, the peripheral airways 
collapse during expiration, obstructing the oscillatory pressure signals from 
reaching the alveoli. Instead they are reflected from the airway walls proximal to 
the site of obstruction, Figure 7. The resulting reactance, estimated by measuring 
the pressure-flow relationship at the airway opening will be more negative during 
expiration than during inspiration, creating a within-breath reactance difference, 
∆Xrs. In two small studies, the ∆Xrs cut-off 0.28 kPa·s·L-1 was found accurately 
to detect EFLT validated against the Mead and Whittenberger and the NEP 










Volume                                                       Volume 
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Figure 7. Detecting EFLT by the FOT technique: Pressure oscillations are reflected from the sites of 
obstruction during expiration, while they travel all the way to the alveoli during inspiration, generating a 
within-breath difference in the impedance parameters.  
 
1.9 Clinical significance of EFLT 
Ventilation can increase to meet the demands of exercise by either increasing the 
respiratory rate and/or by increasing the tidal volume. In COPD patients with 
expiratory flow limitation, tidal volume is unable to expand by encroaching on 
the expiratory reserve volume.  All increments must come from the inspiratory 
capacity, leading to a gradual dynamic hyperinflation at progressing exercise. 
When hyper inflating the lungs, the respiratory muscles are shortened and have to 
work at much less favorable force-length relationships, thus increasing the work 
of breathing [81]. At the same time the end-expiratory lung volume increases, 
increasing the number of poorly ventilated alveoli [82]. This increased alveolar 
dead space may cause ventilation/perfusion abnormalities, and lead to retention 
of CO2. Airway obstruction also leads to an increased intra-thoracic pressure 
which in turn may reduce the cardiac output [83]. 
EFLT and dynamic hyperinflation have strong associations to the sensation of 
dyspnea. Although many factors contribute to this subjective sensation, the 
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lung volume is thought to be a major contributor [74]. The combined negative 
effects of dynamic hyperinflation and exertional dyspnea reduce the exercise 
capacity of patients with EFLT.  
EFLT has also been proposed as a stage in the development to symptomatic 
COPD in smokers where the airway closure during tidal volume breathing may 
cause mechanical injury leading to disease progression [84]. And there is a strong 
association between COPD and exacerbations. As airflow limitation increases 
with an exacerbation the prevalence of EFLT increases, and as the exacerbation 
resolves, the EFLT index, ∆Xrs has been shown to decrease [85]. It is not known 
if the presence of EFLT by itself actually increases the risk of COPD 
exacerbations, but there are mechanisms indicating that this might be the case. 
Coughing plays an important role in maintaining the airways by removing excess 
secretions from the respiratory tract [86]. Under normal circumstances a cough 
creates an increase in the airflow velocity within an airway. This is commonly 
intense enough to move mucus and secretions. But if maximal velocity within 
that airway is reached already at tidal volume breathing, coughing may be less 
efficient in eliminating mucus [87]. An inefficient cough mechanism might lead 
to increased mucus retention, increasing the risk of pulmonary infections, hereby 
increasing the risk of COPD exacerbations. EFLT is thought to be associated with 
an emphysematous phenotype in COPD where prognosis might differ from other 
COPD patients, but further studies are needed to link EFLT to certain phenotypes 
[71]. 
Although many techniques are established to evaluate EFLT, no gold standard 
exists [29, 30, 69, 75-77, 88]. We found the FOT technique attractive since it 
does not require complex panting maneuvers, and due to its high feasibility in the 




   
16
Table 2. Selected studies reporting FOT measurements in COPD patients and smokers 
Study Year Participants N Findings 
Farre [57] 1998 COPD patients 5 Measuring respiratory mechanics in mechanically ventilated COPD 
patients 
Janssens [24] 2001 Elderly 240 FOT was found to have a higher feasibility than spirometry in elderly 
     
Dellaca [30] 2004 COPD/controls 22 Agreement between FOT and the Mead and Whittenberger method in 
detecting EFLT. 
Johnson [31] 2006 COPD patients 39 FOT changes following COPD exacerbations 
Dellaca [29] 2007 COPD patients  Agreement between FOT and the NEP technique method in detecting 
EFLT. 
Faria [28] 2009 Smokers 28 Early smoking induced respiratory changes detected by FOT 
Kubota [49] 2009 COPD/controls 38 Low frequency FOT variables are less variable during inspiration than 
during expiration. 
Ohishi [53] 2011 COPD/controls 44 IOS can be used to detect within-breath oscillatory mechanics with a 
high temporal resolution. 
Year: year of publication. N: number of subjects. 
 
 
The present study set out to examine an alternative method to assess lung 
function in elderly and in patients with COPD by evaluating within-breath 
reactance FOT measurements in sequences of tidal volume breathing. We report 
∆ as mean inspiratory minus mean expiratory reactance over several breaths, 
Equation 2. 
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2. Objectives 
We used data from the Bergen Elderly Lung Health (BELH) study, a validation 
study performed on inpatients at the Salvatore Maogeri en Montescano Hospital 
in Milano (Milano study), and the Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate End-points (ECLIPSE) study, with additional 
patients enrolled from our clinical catchment area. 
 
The main object of the study was to evaluate a new method for evaluating 
pulmonary function in elderly and patients with COPD by measuring the mean 
within-breath reactance difference over multiple breaths, ∆.  
 
Paper I: The aim of this cross-sectional study was to establish reference values 
for whole-breath and within-breath impedance measurements in elderly aged 70 
years and older using IOS.   
Paper II: The aim of this clinical validation study was to analyse the agreement 
between two different forcing signals, impulse oscillations and sinusoidal 
pressure oscillations when measuring pulmonary impedance. 
Paper III: The aim of this case-control study was to compare the use of ∆ to 
the tradition breath-by-breath ∆Xrs measurements used to identify EFLT, 
examine within- and between-day reproducibility of ∆, examine factors 
affecting the size of ∆, and to examine the association between ∆ and 
dyspnoea. 
Paper IV: The aim of this longitudinal cohort study was to describe the impact 
of EFLT on morbidity and mortality in a large COPD cohort.   
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3. Methods 
Three studies form the base of this thesis: 
• The Bergen Elderly Lung Health (BELH) Study 
• The Milano study 
• The Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
End-points (ECLIPSE) study  
3.1 The BELH study 
The Bergen Elderly Lung Health Study was a cross-sectional study conducted 
from 1998 to 2000 in elderly subjects aged 70 years and older living in the 
municipality of Bergen [27, 89-92]. We re-examined previously unpublished 
forced oscillation mechanics data from this study. A sex and age stratified sample 
of 319 subjects were drawn from the responders of a respiratory health postal 
questionnaire based on the American Thoracic Society and the Division of Lung 
Diseases questionnaire (ATS/DLD-78) [93]. The never and ex-smoking 
participants, 208 were invited to the clinic to undergo further testing out of whom 
161 participants showed up at the test site, see flowchart, Figure 8. Subjects with 
acceptable and normal spirometry and at least 2 acceptable IOS measurements 
were included in our analysis for paper I, N=75, Figure 3 [26, 27, 94].  
3.1.1 Inclusion criteria:  
• Age >69 years 
• Acceptable spirometry and IOS measurements [26, 94] 
• FEV1 and FVC >80% predicted 
• FEV1/FVC >5 percentile / lower limit of normal 
 
 
   
19
3.1.2 Exclusion criteria:  
• Acute or chronic respiratory disease 
• ATS/DLD dyspnoea grade 4 (after walking 100m on level ground) 
• Heart disease 
• Hypertension if complicated by ATS/DLD dyspnoea grade 3 (ever having 
to stop due to breathlessness on the level) 




Figure 8. Flowchart of the Bergen Elderly Lung Health study 
 
Reasons for exclusion:
13 IOS not pereformed
31 IOS did not meet ERS criteria
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3.1.3 Assessment tools 
Spirometry 
Spirometry manoeuvres were performed according to ATS guidelines sitting, 
wearing a nose clip, using a Vitalograph dry wedge bellows (Vitalograph, 
Buckingham, UK) [26]. Before each session calibration was performed with a 1L 
syringe using repeated strokes up to 9L. The best values for FEV1 and FVC out 
of 3 acceptable manoeuvres were reported. Only 119 of the original 161 
participants were able to complete an acceptable spirometry [26]. Reasons for not 
being able to perform spirometry were: Coughing within the first second, 
leakage, too early termination, and not being able to follow instructions. 
 
Forced Oscillation Technique 
FOT measurements were performed on a Masterscreen IOS (Erich Jaeger Gmbh, 
version 4.5). At the beginning of each day a 2L syringe and a reference resistance 
of 0.2 kPa·s·L-1 were used for volume and pressure calibration. IOS was 
performed sitting, wearing a nose clip, supporting cheeks with both hands, and 
using a cylindrical cardboard mouthpiece. Each subject performed 2-5 
measurements of 30 seconds tidal volume (VT) breathing. An on site evaluation 
of acceptability was performed by the technician. In addition the original 
recordings were reviewed retrospectively using the ERS task force 
recommendations, which were not available at the time of the recordings [94]. 
Additional 48 tests were excluded due to signs of leakage around the mouthpiece 
(N=4), hyperventilation (N=20), and glottis movement (N=24). 117 test subjects 








IBM SPSS Statistics, Version 18 was used for data management and analysis. 
 
Descriptive analysis 
Data were presented as mean ± standard deviation, median (95% confidence 
interval), median (interquartile range), or percentage. Normal distribution was 
assessed by histograms, Q-Q plots, and by Kolmogorov-Smirnov and Shapiro-
Wilks tests of normality [95, 96]. Repeatability of the parameters was assessed 




Non-parametric impedance parameters were normalized using natural log (ln) 
transformation [98]. Predictive equations were generated using multiple linear 
regression for whole breath, mean inspiratory, and mean expiratory values 
separately for men and women examining the relationship between the IOS 
variables and the independent variables of height and weight [99]. Mean of IOS 
measurements were back-transformed from the geometric mean.  
 
3.1.5 Ethics 
Participation in the study was voluntary. Oral and written information was given, 
and informed consent obtained from all study subjects prior to enrolment. The 
study was reviewed and approved by the Western Norway Regional Committee 
for Medical and Health Research Ethics. 
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3.2 The Milano study 
The Milano study (2008-2009) compared FOT measurements with different input 
signal waveforms. Test subjects were all inpatients at the Salvatore Maogeri en 
Montescano rehabilitation hospital. 20 clinically stable patients reporting 
respiratory symptoms were recruited. The study population consisted of 16 men 
and 4 women. In 13 patients COPD was verified by spirometry. 7 patients were 
obese with a BMI >30 kg/m2.  Pre- and post bronchodilator spirometry and FOT 
were performed in order to estimate the agreement between pulmonary 
impedance measurements obtained with sinusoidal pressure oscillations and 
impulse oscillations.  
 
3.2.1 Inclusion criteria 
• Inpatient at the Salvatore Maogeri en Montescano rehabilitation hospital  
• Respiratory symptoms 
• Being clinically stable at the time of the measurements 
• Signed, and dated informed consent 
 
3.2.2 Exclusion criteria 
• Unstable disease at the time of the measurements. 
• Failure to perform the measurements. 
 
3.2.3 Assessment tools 
Height and weight was measured. Pre- and post bronchodilator spirometry were 
performed using a body plethysmograph (Masterlab, Jaeger, Würzburg, 
Germany). 2 patients failed to perform acceptable spirometry, but were still kept 
 
 
   
23
in the sample. FOT measurements were sampled using sinusoidal pressure 
signals generated with a commercial loudspeaker (HS250, Ciare, Ancona, Italy) 
and with impulse oscillations generated by a modified commercially available 
impulse oscillations system (Masterscreen IOS, Carefusion Hoechberg, 
Germany). Both pressure signals were measured using the pressure and flow 
transducers of the Masterscreen IOS, synchronized with the internal clock of the 




IBM SPSS Statistics, Version 23 (SPSS Inc., Chicago, Illinois, USA), R 3.3.1 
GUI (The R Foundation for Statistical Computing, Vienna, Austria), and 




Data were presented as mean ± standard deviation, absolute count or percentage. 
Normal distributions were assessed using histograms, Q-Q plots, Kolmogorov-
Smirnov, and Shapiro-Wilks tests of normality [95, 96]. Non-parametric data 
were compared using Wilcoxon signed rank test. Coefficient of variation (CV) 
was used a measure of repeatability [97]. The agreement between sinusoidal 
pressure oscillations and impulse oscillations was shown by scatterplots and 
Bland-Altman plots. Measurement repeatability (or short-time variability) was 
calculated as the 2.5 and 97.5 percentiles of the distribution of the differences 
between two consecutive measurements using data from the COPD patients 
ECLIPSE/BCCS study [34]. Relationship between the two measurements was 
analysed using Deming regression. The resulting regression lines and confidence 
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intervals were compared with the calculated measurement repeatability. 
 
3.2.5 Ethics 
Written, informed consent was obtained from all study subjects. The institutional 
research ethics committee approved the study. 
3.3 The ECLIPSE study 
The ECLIPSE study (2006-2010) was as a large, longitudinal, non-
interventional, case-control study designed to identify new markers of disease 
progression [100]. 46 centres in 12 countries participated in the study. Our site, 
Haukeland University Hospital was one of the largest contributors with 400 
COPD cases and 147 smoking controls. Participants were recruited from the 
general population, patient out-clinics, and hospitals with a majority having 
participated in previous studies performed at our site, the Hordaland County 
Cohort Study and the GenKOLS study [101, 102]. No non-smoking controls 
were recruited from our site to the official ECLIPSE study, however, a local 
addition was added following the same entry criteria: 46 non-smoking and 36 
smoking controls and 25 COPD patients. These study subjects did not attend all 
visits. A flowchart illustrating the patient inclusion is shown in Figure 9. The 
Bergen cohort with the additional study subjects is also known as the Bergen 
COPD Cohort Study (BCCS) [103].  
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Figure 9. Flowchart illustrating the patient inclusion of the ECLIPSE/Bergen COPD Cohort Study 
3.3.1 Inclusion criteria 
COPD cases 
• Age 40-75. 
• Baseline post-bronchodilator FEV1 <80% predicted and a FEV1/FVC ≤ 
70%. 
• Smoking history ≥10 pack-years. 
• Signed, and dated informed consent 
• Being able to complete the study. 
 
Smoking controls 
• Age 40-75. 
• Baseline post-bronchodilator FEV1 >85% predicted and a FEV1/FVC 
>70% 
• Smoking history ≥10 pack-years. 
• Signed, and dated informed consent. 
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• Being able to complete the study. 
• Available for the duration of the study. 
 
Non-smoking controls 
• Age 40-75. 
• Baseline post-bronchodilator FEV1 >85% predicted and a FEV1/FVC 
>70% 
• Smoking history <1 pack-year. 
• Signed, and dated informed consent. 
• Being able to complete the study. 
• Available for the duration of the study. 
 
3.3.2 Exclusion criteria 
Cases and controls 
• Known respiratory disorders other than COPD. 
• Prior medical history of significant inflammatory disease other than 
COPD. 
• Severe α1-antitrypsin deficiency. 
• Having undergone lung surgery. 
• A diagnosis of cancer within the last 5 years. 
• Serious uncontrolled disease likely to interfere with the study or to likely 
impact subject safety. 
• Taking part in a blinded drug study. 
• Participation in a study with radiation exposure. 
• Substance abuse. 
• Blood transfusion in the 4 weeks prior to study start. 
• Having a COPD exacerbation within 4 weeks of enrolment.  
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• Inability to walk. 
• Participant, or a family member of the participant working in the study. 
• Use of oral steroids for stabile COPD. 
 
Figure 10. Timeline and number of COPD patients at each visit of the ECLIPSE/Bergen COPD Cohort 
Study. For the controls, the study only used baseline data. Visit 2 was performed 3 months after baseline. 
 
3.3.3 Assessment tools 
At baseline, study subjects were assessed with a physical examination, blood gas, 
pulmonary function tests, measurements of lung volumes, six-minute walk test, 
and a booklet of questionnaires, including the ATS/DLD-78, the Saint George 
Respiratory Questionnaire (SGRQ-C), and the modified Medical Research 
Council dyspnoea scale score (MMRC) [93, 104-107]. Exacerbations were 
widely defined as a worsening of respiratory symptoms for 2 following days or 
more. In the present study only exacerbations requiring the use of antibiotics or 
systemic corticosteroids and exacerbations requiring hospitalization were 
included. Exacerbation history was recorded at baseline. Test subjects were 
called in for a total of 8 visits: at baseline, at 3 months, and then half-yearly for a 
total of 3 years, Figure 10. Exacerbations were assessed retrospectively, every six 
months in a clinical interview. Table 3 gives an overview of the assessment tools 
used at the different visits, which we have referred to in paper III and IV. The 
questionnaires used to assess exacerbations are shown in the Appendix. 
 
6 months 
COPD    425    351    362        384           348      354           321      329 
Controls    229    164    140        174          144      142           133      141 
Visit number 
1 year 2 years 3 years 
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Table 3.  Assessment tools in the ECLIPSE/Bergen  
COPD Cohort Study 
 
 Visit number  
 1 2 3 4 5 6 7 8 
Physical examination * # * * * * * * 
  Blood gas *  * * * * * * 
Questionnaires         
  SGRQ-C *   *  *  * 
  ATS/DLD-78 *        
  MMRC *   *  *  * 
  Exacerbations   * *  *  * 
Spirometry * * * * * * * * 
IOS * * * * * * * * 
Plethysmography *   *  *  * 
Six-minute walk test *   *    * 
SGRQ-C: Saint George Respiratory Questionnaire 
[105]. ATS/DLD-78: American Thoracic Society and 
the Division of Lung Diseases questionnaire [93]. 
MMRC: modified Medical Research Council dyspnoea 
scale score [104]. IOS: Impulse Oscillometry System.   
*Performed. #: If needed. 
 
3.3.4 Pulmonary function tests 
Spirometry and IOS 
Pre- and post- bronchodilator (0.4 mg salbutamol) spirometry and FOT 
measurements were performed by trained personnel each visit in accordance with 
agreed standards on a Masterscope CT Impulse Oscillation System (IOS) (Jaeger, 
Hoechberg, Germany) [26, 94]. Before each session a 3L syringe and a reference 
resistance of 0.2 kPa·s·L-1were used for volume and pressure calibration. The 
highest values from at least 3 acceptable spirometry procedures were used to 
determine FEV1 and FVC. FEV1 % predicted was calculated using local 
reference values [19, 26]. IOS was performed sitting, wearing a nose clip, and 
supporting cheeks with both hands. Each subject performed 3 acceptable 
measurements of 30 seconds VT breathing. Acceptability was assessed on site by 
visual inspection of the patient while performing the test and by a review of the 
recordings using the ERS task force recommendations [94]. Both whole- and 
within-breath (inspiratory and expiratory) values were reported for: Resistance at 
5 Hz (Rrs5), reactance at 5 Hz (Xrs5), and resonant frequency (ƒres). Mean 
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within-breath reactance at 5 Hertz, ∆ was calculated for each measurement 
averaged over the 30-second sampling period, Equation 2.  
 
Plethysmography 
Whole-body plethysmography was performed on a MasterscreenTM body 
plethysmograph (Jaeger, Hoechberg, Germany). Before each session, volume 
was calibrated, and before each individual examination, the test subject weighed, 
and allowed a 5 minutes rest. 3 acceptable tests were performed according to 
international standards [108]. Variables used in this study were residual volume 
(RV), total lung capacity (TLC), and inspiratory capacity (IC). 
 
3.3.5 Six-minute walk test 
Only the COPD cases performed the six-minute walk test (6MWT). The test was 
performed in accordance with the ATS guidelines in a straight, 30 meter hospital 
corridor, supervised by a trained technician [106]. The oxygen saturation was 
measured both before and directly after the test using a Nonin 8500 Handheld 
Pulse Oximeter (Nonin Medical, Inc., Plymouth, Minnesota, USA). Safety 
criteria for stopping the test were chest pain, intolerable dyspnoea, diaphoresis, 
leg cramps, if the patient started staggering, and if the patient appeared pale or 
ashen. If a desaturation ≤86% was found at the end of the test, the COPD patient 
was referred to pulmonary rehabilitation for evaluation of oxygen treatment. The 
level of dyspnoea and fatigue was evaluated using Borg scale in the beginning 








IBM SPSS Statistics, Versions 20-22 (SPSS Inc., Chicago, Illinois, USA) and 




Data were presented as mean ± standard deviation, interquartile range, 95% 
confidence interval, absolute count, or percentage. Normal distributions were 
assessed using histograms, Q-Q plots, Kolmogorov-Smirnov, and Shapiro-Wilks 
tests of normality [95, 96].  
 
Asociations, binary classifiers, and grouping of cases 
Dependence between variables was assessed with Pearson’s correlation 
coefficient or Spearman’s rho [110]. Means were compared using t-test or Mann-
Whitney U test when appropriate [111]. In paper III receiver operating 
characteristic (ROC) curves were used to illustrate the performance of ∆ and 
FEV1 to detect dyspnoea as their discrimination threshold were varied [112]. In 
line with the current GOLD guidelines, an empirical threshold of ≥2 of the 
modified Medical Research Council dyspnoea scale score (MMRC) was used to 
define dyspnoea [67, 104, 107]. The best composite specificity and sensitivity for 
dyspnoea (MMRC ≥2) was found at ∆>0.1   kPa·s·L-1 [34]. In paper IV cases 
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Variability 
Coefficient of variation (CV) was used a measure of repeatability [97]. 
Consistency between repeated measurements of ∆ with the breath-by-breath 
and the multiple-breath approach was tested with intraclass correlation 
coefficient (ICC) [113]. The within-day repeatability of ∆ was shown in a 
modified Bland-Altman plot, and a timeline plot was used to illustrate the 
reproducibility over the course of the 3-year study in cases and controls [114]. 
 
Longitudinal data and survival analysis 
Negative binomial regression was used to analyse annual exacerbation rates over 
the 3-year study [115]. The analysis accounts for the yearly variability among 
test subjects. We adjusted for age, sex, FEV1, in addition to a binary classifier 
identifying COPD patients with ≥2 exacerbations the year prior to inclusion. The 
parameter effects of the negative binomial regression were reported as rate ratios 
(RR), 95% confidence interval, and p-values. Exacerbations were also 
investigated by time to first event analysis with Kaplan-Meier survival analysis 
and 1-survival plots. The patients were grouped based on occurrence of ∆ 
>upper limit of normal at baseline and dichotomized at FEV1 50 % predicted [67, 
116, 117]. In our survival analysis Kaplan-Meier product limit estimates for 
patients with and without evidence of EFLT at baseline were plotted in COPD 
patients with FEV1 >50 % predicted and in COPD patients with FEV1 <50 %, 
and differences between groups analysed using Log-rank test. Hazard ratios were 
obtained using Cox proportional hazards regression [116, 117]. 
 
3.3.7 Ethics 
Participation in the study was voluntary. Oral and written information was given, 
and informed consent obtained from all study subjects prior to enrolment. The 
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ECLIPSE/BCCS was approved by the Western Norway Regional Committee for 
Medical and Health Research Ethics (REK 165.08) and performed in agreement 
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4. Synopsis of papers 
4.1 Paper I 
Reference values for within-breath pulmonary impedance 
parameters in asymptomatic elderly 
Aarli BB, Eagan TM, Ellingsen I, Bakke PS, Hardie JA. Clin Respir J. 2013 Jul; 
7(3): 245-52. doi: 10.1111/j.1752-699X.2012.00312.x. Epub 2012 Aug 20. 
The forced oscillation technique measures airway mechanics non-invasively 
during normal tidal breathing. By evaluating variations in the pulmonary 
reactance in the respiratory cycle, a method has been developed which accurately 
detects EFLT [29, 30]. However, at the time of the study, reference values for 
FOT parameters in elderly were very limited, particularly using impulse 
oscillations. Reference values for partitioned inspiratory and expiratory 
measurements used by the method were non-existent [32, 41]. The aim of this 
study was to present reference values for oscillatory lung mechanics in healthy 
elderly.  
An age- and sex-stratified sample was drawn from healthy, non-smoking 
responders of a postal questionnaire study in elderly aged >70 years in the city of 
Bergen [89]. Study subjects performed both spirometry and FOT measurements 
on an Impulse Oscillometry System (IOS). 75 study subjects had normal and 
acceptable spirometry and at least two acceptable IOS measurements [26, 94]. 
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Predictive equations were generated for whole-breath and within-breath 
impedance FOT parameters were created separately for men and women using 
multiple linear regression [99]. The paper reports reference values for whole-
breath as well as within-breath FOT parameters in healthy elderly aged >70 
years. In this healthy elderly population, ∆ was around zero and the 95 
percentile in men and women, 0.26 and 0.24 kPa·s·L-1 consecutively. Only one 
subject had ∆ above the defined threshold of tidal expiratory flow limitation. 
4.2 Paper II 
Agreement between sinusoidal and impulse oscillations when 
measuring pulmonary impedance 
Aarli BB, Govani L, Pompilio PP, Baldi S, Hardie JA, Dellaca RL. In manuscript 
form: to be submitted to the Journal of Respiratory Physiology and Neurobiology 
in 2017. 
 
Several different input signals are presently used to measure pulmonary 
impedance: sinusoidal pressure oscillations, pseudo-random noise, and impulse 
oscillations. In linear systems, the responding pulmonary impedance should be 
the same.  In nonlinear systems, which may occur in pulmonary disease with 
airway obstruction, this might not apply. The aim of this study was to test the 
agreement between sinusoidal pressure oscillations and impulse oscillations. 
20 patients who reported respiratory symptoms were recruited from inpatients at 
the Salvatore Maogeri en Montescano rehabilitation hospital. Pre- and post 
bronchodilator FOT and spirometry were performed with both impulse 
oscillations generated by an IOS commercial device, and sinusoidal pressure 
oscillations generated by a homemade loudspeaker system. Only the input signal 
was changed while transducers and breathing circuits were the same. 
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A wide range of spirometry and Zrs measurements was found in this mixed 
group of patients. EFLT was detected in 17 out of 36 FOT measurement using the 
established ∆Xrs threshold 2.81 H2O·L-1·s [30]. In non-EFLT patients, good 
agreement was found using the two different forcing signals. In EFLT patients, 
variability of Rrs and Xrs exceeded the expected biological variability. Rrs 
values measured by impulse oscillations were significantly higher than the 
sinusoidal pressure oscillation measurements in the EFLT patients. 
Conclusion: Compared with sinusoidal pressure oscillations, impulse oscillations 
overestimate the Rrs measurements, but only at pathologically high impedance 
measurements found in EFLT patients. 
4.3 Paper III 
Variability of within-breath reactance in COPD patients and its 
association with dyspnea  
Aarli BB, Calverley PMA, Jensen RL, Eagan TM, Bakke PS, Hardie JA. Eur 
Resp J. 2015. Mar; 45(3): 625-34. Oct 30.  
The forced oscillation technique can be used to identify EFLT by detecting 
changes in reactance over the respiratory cycle [29, 30]. A cut-off in within-
breath reactance, ∆Xrs has been defined to identify single breaths as tidal 
expiratory flow limited, however, evidence suggest that presence of EFLT varies 
from breath to breath [30]. This paper explores a new method to identify EFLT 
using a mean multiple breath ∆ approach. We investigate the variability and 
reproducibility of this method and examine how ∆relates to the sensation of 
dyspnea. 
This study reports the results form the Bergen cohort of the ECLIPSE study, 
consisting of 425 stable COPD patients and 229 controls [67]. Study subjects 
 
 
   
37
were called in for 8 visits over 3 years performing a wide range of tests and 
questionnaires, including spirometry and FOT using impulse oscillations. 
Healthy controls generally had very low ∆ measurements with a median 
around zero, and a 95th percentile at 0.07 kPa·s·L-1 with little variation between 
measurements. The COPD patients had higher ∆ and more variability. Using 
receiver operating characteristics analysis, we found the cut-off ∆ ≥0.1 
kPa·s·L-1 to identify patients with significant dyspnoea, defined as having a 
modified Medical Research Council Dyspnoea scale score ≥2 [104].  
We describe a new method to assess EFLT using a multiple breath approach and 
explore the variability of the method. A cut-off in ∆ ≥0.1 kPa·s·L-1 was found 
to identify test subjects more likely to report dyspnoea.  
4.4 Paper IV 
The association of tidal EFL with exercise performance, 
exacerbations, and death in COPD 
Aarli BB, Calverley PMA, Jensen RL, Eagan TM, Bakke PS, Hardie JA.  
Accepted for publication in the International Journal of Chronic Obstructive 
Pulmonary disease, May 2017. 
EFL frequently presents already at tidal breathing in COPD and can be detected 
by FOT during a single breath when ∆Xrs exceed 0.28 kPa·s·L-1 [30, 34, 70]. 
This study investigates the association of mean within-breath reactance measured 
over multiple breaths, ∆ with exercise performance, exacerbation rate, and 
mortality.  
425 COPD patients were followed for 3 years/8 visits, reporting spirometry and 
impulse oscillation mechanics. Exercise performance was evaluated by the 
6MWT and respiratory symptoms, exacerbations, and hospitalizations recorded. 
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The 5-year mortality statistics was retrieved retrospectively. Patients were 
grouped into 3 according to ∆ at baseline using the 97.5th percentile/ULN of 
the healthy controls and the established threshold of EFLT as cut-offs. Annual 
exacerbation rates were analysed by a negative binomial model in the three 
groups, supplemented by time to first event analysis for exacerbations, 
dichotomizing at the ULN. 
While COPD patients with ∆ <ULN (0.09 kPa·s·L-1) had a stable 6MWD. 
The patients with ∆ ≥ULN declined significantly in 6MWD had lower FEV1, 
more exacerbations, and a shorter time to first exacerbation and hospitalization. 
Patients with FEV1 >50% and ∆ ≥ULN had significantly higher mortality. 
Conclusions: Patients with ∆ ≥ULN deteriorated in exercise performance, had 
more exacerbations and hospitalizations, and in COPD patients with moderate 
airway obstruction, also a higher mortality. We propose ∆ is an independent 
prognostic marker in COPD. 
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5. Discussion 
5.1 Methodological considerations 
5.1.1 Study design 
The papers included are based on 2 observational studies performed years apart, 
the BELH and the ECLIPSE, and a small validation study performed in Milano. 
Different study designs chosen for each paper:  
• Paper I reports reference value equations generated from healthy elderly in 
the cross-sectional BELH study.  
• Paper II is a validation study investigating the agreement between two 
forcing signals used in FOT: sinusoidal pressure oscillations and impulse 
oscillations. 
• Paper III use data from the prospective, case-control ECLIPSE study. 
Variability of within-breath reactance was tested in cases and controls. 
The longitudinal design allowed for the assessment of reproducibility both 
at baseline and over time.  
• Paper IV used a prospective cohort study design, following COPD cases 
only in the ECLIPSE study. It investigates the associations between 
presence of EFLT and adverse outcomes such as deterioration in exercise 
capacity, exacerbations, hospitalizations, and death.  
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Table 4. Design and study population in the four papers 
 
Paper Design N Men Age Participants 
I Cross sectional  75 53 % 79 ± 7 Healthy elderly 
 BELH study     
      
II Validation study 20 85 % 69 ± 10 Inpatients at a 
rehabilitation hospital 
      
III Prospective case-control 654 57 % 60 ± 9 Controls (N=229) 
 3-year follow up     GOLD 2 (N=179) 
 ECLIPSE/BCCS study    GOLD 3 (N=186) 
     GOLD 4 (N=60) 
      
III Prospective cohort study 425 60 % 63 ± 7 GOLD 2 (N=179) 
 3-year follow up     GOLD 3 (N=186) 
 ECLIPSE/BCCS study    GOLD 4 (N=60) 
Data presented as mean ± standard deviation, percentage, or absolute numbers. BELH: 
Bergen Elderly Lung Health Study. ECLIPSE/BCCS: Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints/Bergen COPD Cohort 
Study. GOLD: Global Initiative for Chronic Obstructive Lung Disease [67]. 
 
5.1.2 Patient selection 
The inclusion and exclusion criteria have previously been outlined in the 
Methods section, chapter 3. This section describes the recruitment process of the 
different studies. For the longitudinal ECLIPSE/BCCS the dropout rate is also 
discussed. 
The BELH study 
The BELH study participants were recruited from the municipality of Bergen. 
Although covering a relatively large area, 465 km2, about 97% of the population 
of Bergen lives in urban areas [119]. For our target population, the Norwegian 
population in general, the corresponding number is 81% [120]. In 1972 the 
municipality of Bergen merged with four surrounding and at the time relatively 
rural municipalities, Arna, Fana, Laksevåg, and Åsane, increasing it’s population 
with 90.000 people [121].  Many subjects included in our study have lived in 
rural areas parts of their lives, reducing possible differences derived from 
differences in the proportion in elderly living in rural and urban areas between 
 
 
   
41
the study and the target population. The non-responders have previously been 
described [89].  
The Milano study 
The study was performed from February 2008 to June 2009. Inpatients at the 
Salvatore Maogeri en Montescano rehabilitation hospital with respiratory 
symptoms, in whom COPD was suspected, were recruited. Out of 22 patients 
included in the study, 2 patients were excluded due to missing data. 2 patients 
unable to perform spirometry, but with valid sinusoidal and IOS measurements 
were still kept in the sample. As results are used to make inferences on a sample 
of COPD patients, it is a disadvantage that only 65% of the study subjects 
actually had a spirometry confirmed diagnosis of COPD. However, the goal of 
the study was to recruit patients with a wide range of spirometric measurements 
and a varying degree of airway obstruction in order to have an equally large 
spread in the FOT measurements. Due to low sample size, the study must be 
regarded as hypothesis testing more than validating. 
 
The ECLIPSE study 
COPD cases were recruited from the GenKOLS study performed in 2003-2004. 
Screen failures from the GenKOLS study with FEV1 80-90% at risk of 
developing COPD were re-examined and included if they met entry criteria. 
Patients were recruited from the out-clinic and the pulmonary rehabilitation 
referrals of the Department of Thoracic Medicine at Haukeland University 
Hospital, and from the to the out-clinic at the Department of Medicine at the 
following hospitals: Stord, Førde, Kristiansand, and Voss. In addition some 
patient were referred from a private pulmonology practice in Straume. 
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Controls were mainly recruited from the previous studies GenKOLS and the 
2003 follow-up of the Hordaland County Respiratory Health Survey [122]. Only 
controls living in our clinical catchment area were included. 
Dropout rate was approximately 23%, deaths included from baseline to the final 
visit, Table 5. This is lower than comparable longitudinal COPD studies [123, 
124].  
 
Table 5. Deaths and dropouts during the 3-year study period 
 N % 
Died  41 10 
IOS not performed at the final visit 16 4 
Refused further participation 8 2 
Excluded due to use of oral steroids 8 2 
Excluded after being diagnosed with pulmonary cancer 5 1 
Other causes 18 4 
TOTAL 96 23 
 
 
5.1.3 Internal validity 
Internal validity is the degree to which the results are determined by independent 
variables and not to some other explanations. Research designed to investigate 
cause-and-effect relationships may be affected by various systematic errors, 
which may affect the outcome.  
Selection bias 
The BELH study recruited randomly among the healthy responders of a 
respiratory questionnaire sent to the elderly in the general population of Bergen. 
Steps taken in the recruitment process to minimize the risk of selection bias was 
stratifying for age and sex 
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In the ECLIPSE/BCCS study the smoking controls were on average 10 years 
younger than the COPD patients [34]. We do not know if the ∆ 97.5th 
percentile used to define the ULN would have been higher in a control 
population more similar to the COPD cases in age. Gender differences may also 
have affected the results. Among COPD patients 60% were male [36]. Matching 
for age and sex could have secured a more uniform patient population, possibly 
reducing the risk of age and sex being confounders. 
 
Information bias 
In order to minimize the risk of information bias, validated questionnaires were 
used [93, 104, 105, 109]. A prospective design, collecting information and 
measurements at each visit not to long apart, reduces the risk of recall bias. 
Socially sensitive questions such as smoking history are often underestimated 
[125]. To improve our smoking history estimates, detailed registration of 
smoking habits were registered at baseline. Only pulmonary function tests 
equipment compliant with the regulations of European Medical Device Directive 
were used. The Erich Jaeger/Carefusion spirometer/IOS apparatuses used are 
certified according to the International Organization for Standardization, ISO 
9001/IEC 13485. Spirometry, IOS and plethysmography were performed 
according to ATS/ERS standards [5, 94, 108]. The measurement and calibration 
procedures are reported in the methods section, Chapter 3.  
 
Confounding 
Steps taken in the BELH study to avoid confounding were restricting admission 
to the study by selecting a group of healthy elderly with similar levels of 
confounding factors. Only elderly aged >69 years with FEV1 and FVC >80% 
predicted and a FEV1/FVC >LLN with no acute or chronic respiratory disease, 
heart disease, hypertension if complicated by ATS/DLD dyspnea grade 3, or 
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ATS/DLD dyspnea grade 4. A randomized selection was chosen among the 
healthy responders to undergo further testing.  
 
A consideration of confounding effects in the ECLIPSE/BCCS study was made 
when choosing the inclusion and exclusion criteria, i.e. restricting the study by 
only including COPD patients with a smoking history ≥10 pack-years, reduces 
the possible confounding effect caused by tobacco smoking.  
 
Controlling for confounding was performed in the multiple regression models 
used in both the BELH and the ECLIPSE/BCCS studies, keeping only 
statistically significant variables in the models. In the Milano study the 
experimental setup was designed specifically to minimize confounding factors 
related to the FOT device and the measurement situation, i.e. measurements 
using sinusoidal pressure oscillations were performed in the same session as 
impulse oscillations changing only the forcing signal, while the sensors and 
circuits were the same. The order of the measurements, whether sinusoidal or 
impulse oscillations were performed first, was altered randomly.  
Random error 
The number of test subjects in the BELH study, was relatively small (N=75), 
lowering the precision of the reference equations generated [35]. The Milano 
study included 36 FOT measurements with both sinusoidal and impulse 
oscillations performed in only 20 patients. Due to low sample size, we cannot 
exclude that the overestimation of Rrs using impulse oscillations could have been 
caused by random error. The ECLIPSE study’s sample size was considerably 
larger, increasing the precision of the estimates. 
5.1.4 External validity 
To ensure generalizability of the study population and to reduce the risk of 
selection bias, a randomized selection of the healthy respondents was chosen and 
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called in for further testing in the BELH study. A random sample of the non-
responders interviewed by telephone, found only minor differences between 
responders and non-responders, minimizing the risk of a non-responder bias [89]. 
Sampling bias 
A sample is biased if some members of a population or patient group are more 
likely to be included than others. In the ECLIPSE/BCCS study the COPD 
patients were recruited mainly from hospital out-clinics, a population with higher 
morbidity than general population [102]. At the same time the COPD patients 
with the most advanced disease may have been underrepresented due to inability 
to participate. The study required being able to meet at the hospital to participate 
in the visits. A considerable disability and limitations in performing activities in 
daily living is associated with very advanced airway obstruction, making 
travelling to and from the hospital more difficult. For this reason GOLD grade 4 
patients may have been more reluctant to participate among potential candidates 
for inclusion. Thus, it is likely that the majority of included COPD cases in the 
study were more afflicted than the COPD population at large, yet some 
particularly afflicted patients were probably excluded.  
The healthy controls were volunteers from previous cohort studies, and not 
randomly selected. There is some possibility for selection of controls particularly 
worried about their own health, either being very health-conscious and thus 
healthier than the average population, or by knowing that they have a potential 
for adverse health. Previous non-response studies found response rate to drop 
significantly with old age [89], non-responders were more likely to be smokers 
and to have a higher burden of respiratory symptoms [126], additional factors 
increasing the risk of non-response were unemployment, being a student, or 
being retired [127]. A high response rate counteracts response bias. The 
ECLIPSE/BCCS study had a response rate of 69 % [128]. 
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In the ECLIPSE study, several facilities participated in recruitment, covering an 
area, which included most municipalities in Hordaland County, both urban and 
suburban. A few test-subjects were also added from Vest Agder County. 
Although study participants were mostly recruited from Hordaland County, the 
population of Norway is relatively homogenous, allowing us to generalize the 
results to a more universal population. However, being recruited mainly through 
hospitals, the results might be more representative of the hospital seeking COPD 
population rather than the COPD population found in the general population. 
5.1.5 Reliability 
Reliability refers to the consistency of the test results. The ECLIPSE/BCCS 
studied stable COPD. If the test subject was found to have a COPD exacerbation 
at the time of the visit, the visit was rescheduled.  
Exercise capacity was estimated in the ECLIPSE/BCCS study using the well-
established 6MWT [106]. The latest ERS/ATS systematic review on field 
walking tests in COPD reports it to be a reliable test with intra-class correlation 
coefficients in the range from 0.82 to 0.99 [129]. A learning effect has been 
reported with a mean improvement between two tests of 26 meters [129]. For this 
reason a practice test should be considered, but is not mandatory [106]. Due to 
limited resources we did not perform any practice test of the 6MWT. A learning 
effect could mask a decline in the 6MWD from baseline to the final visit.  
 
5.1.6 Data retrieval 
The within-breath FOT parameters were not originally transcribed in the BELH 
or the ECLIPSE study. In the BELH study the within-breath parameters were 
retrieved from the database of the IOS software linking the individual tests to the 
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test subjects id number and the test date. By recalculation, a new screen report 
was generated including the FOT parameters of interest.  
In the ECLIPSE study, the vast number of measurements over the course of the 
visits made such an approach impractical. Instead the complete database from all 
IOS apparatuses used in the study were imported and merged in a computer with 
the newer software (JLAB 5.22), which had a structured query language (SQL) 
export option. Microsoft SQL server and Microsoft Access 2010 were used for 
database management of the JLAB 5.22 SQL export data. Each individual test 
was matched to the punched test in the ECLIPSE study by subject id number, test 
date, and by matching for the post-bronchodilator resonant frequency value. By 
matching for a punched number we were able to exclude the tests discarded on 
site by the technicians, but may have lost some tests due to punching errors.  
 
5.2 Methodological strengths and weaknesses 
5.2.1 The BELH study 
Strengths 
Sex and age stratification ensured a representative number of very old subjects in 
the study. A non-responder bias study where attempts were made to reach hard to 
reach groups, such as people residing in nursing homes found only minor 
differences between responders and non-responders [89]. 
Weaknesses 
As a consequence of a relatively small sample size, reference values generated 
from this study should be interpreted with care, particularly since confidence 
intervals were relatively wide. In addition pulmonary impedance measurement 
data is not normally distributed, and natural log transformations were used. 
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5.2.2 The Milano study 
Strengths 
The experimental setup was specifically designed to eliminate confounding 
factors, and the agreement between measurements using different forcing signal 
was compared with the expected biological variability between two tests using 
impulse oscillations.  
Weaknesses 
Low sample size increases the risk of random errors affecting the results. Even 
though heterogeneity of the study population gave the intended wide spread of 
measurement outcomes, the associations may have been stronger, and more 
clinically relevant if the study had been restricted to COPD patients only. 
 
5.2.3 The ECLIPSE study 
Strengths 
The ECLIPSE study is one of the best characterized, case-control studies 
performed on COPD patients [130]. The longitudinal design and the large 
number of patients and controls made it possible to investigate associations 
between baseline characteristics, disease progression, exacerbations, 
hospitalizations, and death rates.  
Weaknesses 
Our data was restricted to the Bergen cohort of the ECLIPSE study, the only site 
where within-breath oscillatory mechanics were retrieved. If similar data were 
available in the complete ECLIPSE cohort, the study would have had a higher 
power to test clinical endpoints. Single-breath ∆Xrs measurements have been 
validated against both the NEP technique and the esophageal balloon technique 
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to identify single expiratory flow limited breaths. Our measurements represent 90 
seconds samples containing several breaths. When we describe associations with 
breathlessness, exercise capacity, exacerbations, and death using lower ∆ cut-
offs than the established threshold of EFLT, we interpret these borderline 
measurements of ∆ that are beyond what is found in healthy subjects as likely 
to contain some flow-limited breaths. The exact number of flow-limited breaths 
within in each sample is not known, and further prospective studies confirming 
our observations is merited before clinical use is concluded. 
5.3 Discussion of main results 
The study was set out to evaluate a new method for evaluating pulmonary 
function in elderly and patients with COPD by measuring the mean within-breath 
reactance difference over multiple breaths, ∆.  
We explored this in 4 papers where we: 
I. Established reference values for whole-breath and partitioned inspiratory 
and expiratory pulmonary impedance parameters in elderly using IOS. 
II. Evaluated the agreement between ∆ measured by sinusoidal pressure 
oscillations and impulse oscillations.  
III. Compared the use of ∆ to the tradition breath-by-breath ∆Xrs 
measurements used to identify EFLT. Examined the within- and between-
day reproducibility of ∆, examined the factors affecting the size of ∆, 
and examined the association between ∆ and dyspnea. 
IV. Described the impact of EFLT on morbidity and mortality in a large COPD 
cohort.   
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5.3.1 Reference values in asymptomatic elderly 
Human physiology is complex, whereas reference equations used in respiratory 
physiology are much less so. Generally they use less than a handful predictors. 
With only the strongest predictors, variability is only explained in part, and 
relatively large confidence intervals are to be expected. Still, the references 
ranges found in healthy subjects are extremely useful. The reference ranges aid 
us in uncovering respiratory disease in individuals who fall outside these 
boundaries, and we compare with median values of FEV1 when airway 
obstruction is graded. How a healthy reference group of elderly should be 
defined, on the other hand, is difficult to agree on. The WHO defines health as 
follows:  
“Health is a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity.”[131] 
This definition excludes most elderly and cannot be applied. While a 
homogenous reference sample would be the ideal, the elderly is a very 
heterogeneous group [132]. Elderly with identical lung function test may be very 
different with regards to respiratory symptoms, exercise capability, and chronic 
diseases. Differences in smoking habits, working conditions, and lifestyle cause 
huge differences in exposure of air pollutants and other risk factors to evolve. In 
this setting, it is difficult to ensure a representative norm population, and there 
are presently no guidelines defining how reference values should be produced in 
elderly. What is normal aging, and what should be considered pathology? 
Postural changes such as kyphosis and scoliosis with age have considerable 
effect on lung volumes. What is the impact of chronic illnesses? Should 
medication be considered?  
In the absence of reliable reference values, a change in the measurements of one 
individual over time, is much more informative than any single measurement 
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validated against a reference value. This has particularly been true for IOS 
measurements in elderly, where reliable reference studies until recently were 
lacking. As a substitute, reference values for elderly aged >70 years were 
extrapolated from equations generated in subjects <70 years of age [32]. This 
approach is problematic as it assumes existing trends will continue. It disregards 
the large heterogeneity with regards to health and exposure history, which arise 
in the elderly, and it assumes that reference equations generated in younger 
subjects are representative for an elderly population. If reference equations are 
used on different populations than the one that was enrolled and tested to 
generate the equations, they may be misleading. 
Unless elderly are targeted specifically in the design of reference studies, the 
proportion of elderly included may be non-existent or very small. In the recent 
Global Lung Function Initiative (GLI) multi-ethnic reference values for 
spirometry, the proportion of elderly aged >80 years was only 0.8% [20].  
The BELH study supplies reference values for whole-breath and partitioned 
inspiratory and expiratory IOS measurements in healthy elderly aged 70 and 
more. FOT defined EFLT in this sample was very rare. Only 1 out of 75 had ∆ 
measurements above the established threshold of EFLT, which is in stark contrast 
to previous findings by Bisschop et al reporting EFLT in almost half of the 
subjects, examining elderly in France [35]. Selection bias may explain some of 
the differences, but it is likely that the NEP technique used by Bisschop et al has 
a different sensitivity and specificity of detecting EFLT than the FOT technique. 
While a COPD patient may dissolve EFLT identified by FOT by starting to breath 
at a higher lung volume, applying a negative pressure during expiration with the 
NEP technique effectively cancels this possibility to dynamically regulate the 
operating lung volume. Breathing just above the flow limiting end-expiratory 
lung volume, the airway remains open, and pressure/flow signals applied at the 
mouth are allowed to reach the distant alveoli before they are reflected. The 
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flow/volume loops, however, may appear flow-limited. As a consequence, 
borderline breaths will be defined as flow-limited by the NEP technique and as 
normal by the FOT technique.  
 
5.3.2 Forcing signals used to measure pulmonary impedance 
FOT calculates pulmonary impedance at the airway opening when a forcing 
signal is superimposed on normal tidal volume breathing. The forcing signal can 
be either single- or multi-frequency. In single frequency FOT, the test subject’s 
response to a sinusoidal pressure signals is studied. Relatively rapid changes in 
pulmonary impedance may be tracked, such as changes within the respiratory 
cycle [30]. Pulmonary impedance is calculated from the responding pressure and 
flow signals, providing valuable information about the airway mechanics. As the 
technique measures only one frequency at the time, investigating a range of 
frequencies by single frequency FOT would be time consuming. For this reason 
multi-frequency FOT is preferred when examining mechanisms of frequency 
dependency [94]. 
Multi-frequency FOT, such as pseudo-random noise and IOS measures 
respiratory mechanics as a function of frequency, allowing the characteristic 
responses from many different frequencies to be measured at the same time. This 
is useful because different frequencies affect the lungs differently. When 
examining bronchodilator effect of salbutamol in COPD patients by impedance 
measurements in the 4-32 Hertz range, much larger differences are found in 
pulmonary resistance and the reactance at low frequencies than high frequencies 
[133]. The low frequencies seem to penetrate the peripheral airways better, while 
higher frequencies better describe the central airways [134]. 
When multi-frequency signals are used, the complex signal is decomposed into 
its individual frequencies by fast Fourier transformation [32]. This allows us to 
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examine many frequencies in the same timeframe, and allows the use of several 
different signals with different qualities, such as white noise, PRN, and impulse 
oscillations. The calculated impedance should be the same.  
IOS differs from white noise and PRN by using impulse shaped waveforms of 
short duration. Some patients perceive these impulses as slightly unpleasant, but 
in general feasibility is high. The standard IOS setup uses 5 impulses per second, 
which allows for intra-breath analysis comparable to single frequency FOT. As 
the total energy from the pressure signals is applied within a very short 
timeframe, there is less risk of non-linearities caused by dynamic changes in the 
respiratory system [134]. PRN has a poorer time resolution and is not that well 
suited to capture within-breath changes in pulmonary impedance.  
A study by Hellinckx et al compared measurements of pulmonary impedance 
between an impulse oscillations apparatus and a PRN device in a selection of 
healthy test subjects and patients with various respiratory diseases (N=49). In this 
study, the IOS overestimated resistances at low frequency, Rrs5 [47]. The 
differences increased with higher magnitude of the resistance measured, and was 
confirmed in a mechanical model using the wave tube technique. The Xrs 
measurements did not show any systematic differences and were very similar. 
Compared with sinusoidal pressure oscillations, we found similar results. A 
systemic overestimation of Rrs5 by the IOS device was found, while no 
systematic effect was seen on the Xrs5 measurements [37].   
 
5.3.3 Variability of FOT measurements 
Variability of FOT measurements depends on the precision of the measurement 
and the biological variability. The accuracy of the sensors of the IOS used in this 
study, the pneumotach and the pressure transducer, are reported to be ±2% by the 
manufacturer [135]. Biological variability is higher and can be separated into the 
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intra-subject variability, both within a day and the changes over time, and the 
inter-subject variability. The ERS task force recommends using the coefficient of 
variation (CV), defined as the standard deviation ( to the mean (µ), as the main 
index of FOT repeatability and variability, Equation 3 [94].  
 




FOT measurements were performed in one session and should not be affected by 
circadian variation known to exist in pulmonary function [136]. Measurements 
are performed at tidal volume breathing, but may be influenced by the operating 
lung volume, i.e. the degree of hyperinflation, the distensibility at different 
volumes, or if the end-expiratory lung volume is close to the closing volume. 
Glottis closure or swallowing, leads to spikes in the impedance tracings. When 
such artefacts are found in the flow- or impedance tracings, that particular section 
of the test can be removed, calculating impedance from the remaining sample 
[94]. In the BELH- and the ECLIPSE/BCCS studies these individual test were 
discarded [34, 35]. For FOT measurements, a coherence function is normally 
used on site, rejecting measurements with coherence  <95 %. In the BELH and 
the ECLIPSE/BCCS study, coherence was estimated on site. These data are not 
reported. 
Previous reports of within-day variability of the FOT in healthy subjects and 
patients with obstructive pulmonary disease found a within-day variability of Rrs 
between 5-15 %, Table 6. It has been suggested that the short-term variability for 
FOT parameters should not exceed 10 % at frequencies ≥5 Hz [134]. Both the 
BELH and the ECLIPSE/BCCS study had Rrs5 measurements within this 
boundary [34, 35]. However, the main focus of our studies, were the pulmonary 
reactance, including the partitioned inspiratory and expiratory components in 
addition to the within-breath reactance. The BELH study and also previous 
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reports find CVs for Xrs, Xrsinsp, Xrsexp, and ∆Xrs to be higher than 10%, Table 
6, but the CV is by definition unsuited to evaluate variability of pulmonary 
reactance. These measurements are frequently close to zero, in which case the 
CV becomes very high, approaches infinity, or cannot be calculated. Alternative 
measures include the within-subject standard deviation (SDW), the coefficient of 
repeatability (CR), and the intra-class correlation coefficient (ICC) [114, 137]. 
The SDW is seldom reported, but has been found quite low, 0.01-0.04 kPa·s·L-1 
in pulmonary reactance, with Xrsinsp as the most stable measurement [138, 139]. 
For ∆, the SDw is higher in COPD patients than in healthy control subjects, 
and increases with the magnitude of the measurement [34, 37]. 
For spirometric measurements, the optimal method of reporting the short-term 
variability is to estimate the coefficient of repeatability (CR) [140]. CR is 
calculated as 2 times the standard deviation of the differences between two 
measurements [114]. In a multicenter, multi-device study (5 different FOT 
apparatuses), CR was 0.05 kPa·s·L-1 for Xrs5 in healthy adults, N=302 [141]. The 
intra-class correlation coefficient (ICC) for Xrs5, Xrsinsp, and ∆Xrs was ≥0.94 in a 
study on variability of impedance parameters in COPD patients [139].  
The SDW, CR, and ICC show good within-day reproducibility for Xrs5, including 
partitioned inspiratory- and expiratory components, and the ∆Xrs, but variability 
increase with the magnitude of the measurement. We interpret an increased ∆, 
which is below the established threshold of EFLT as a mixture of some normal 
and some flow-limited breaths [30]. The spontaneous variability of ∆Xrs in 
COPD might be caused by a dynamic regulation of the end-expiratory lung 
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Table 6. Within-day variability of the forced oscillation technique (FOT)  



















Neild[142] SIN Healthy 25 Rrs10  11.3    
Neild[142] SIN Asthma 28 Rrs10  10.3    
Timmins[139] SIN COPD 10 Xrs6 0.04 12.6   0.95 
       “ “ “ “ Xrs6 insp 0.01 10.3   0.94 
       “ “ “ “ ∆Xrs 0.04 25.4   0.94 
Robinson[138] “ Healthy children 34 Xrs6 0.01    0.88 
       “ “ Asthma 22 Xrs6 0.02    0.71 
Snashall[143] SIN Asthma 24 Zrs10  4.9    
Guo[41] PRN  Healthy 223 Rrs4-16  7.6    
Janssens[24] PRN Inpatients 67 Rrs4-16  7.9    
Elshout[144] PRN Asthma 30 Rrs8  10.0    
       “ “ “ “ Xrs4-52  26.8    
Noord[145] PRN COPD/asthma 125 Rrs6  15.2    
Watts[146] PRN COPD 302 Xrs5      
Oostveen[141] PRN&IOS Healthy 302 Xrs5    0.05  
Goldman[147] IOS Asthma 24 Xrs5  12.1    
Shiota[46] IOS Healthy 299 Rrs5  5.0    
       “ IOS Healthy “ Xrs5  13.3    
BELH[35] IOS Healthy  75 Rrs5  10    
       “ “ “ “ Xrs5  18    
       “ “ “ “ Xrs5 insp  19    
       “ “ “ “ Xrs5 exp  25    
ECLIPSE[34] IOS COPD  425 Rrs5  5.3    
ECLIPSE[148] IOS COPD 433 Xrs5  10.3    
SIN: Sinusoidal pressure oscillations. PRN: pseudo random noise. IOS: impulse oscillations. SDW: within-subject 
standard deviation (kPa·s·L-1). CV: coefficient of variation. CR: coefficient of repeatability (kPa·s·L-1). ICC: intra-
class correlation coefficient. Rrs: Resistance, number indicates frequency used. Zrs: impedance, number indicates 





The day-to-day variability in lung function testing reflects circadian changes in 
airway resistance from testing on different times of the day, cyclical changes 
over time, such as the influence of sex hormones on asthma in women, [149], and 
in patients with COPD changes related to the disease itself and by bronchodilator 
treatment affecting lung function measurements. Day-to-day variability is larger 
than the within-day variability. For spirometric measurements in COPD patients, 
a change in FEV1 has to exceed 13 % within a day, and 20 % from week-to-week 
to be regarded significant [140]. No formal recommendations for what is to be 
regarded as a significant change has been defined for FOT measurements. The 
day-to-day SDW is larger than the within-day SDW, Table 7. CV is poor for Xrs5, 
Xrsinsp, and ∆Xrs, but as mentioned above should not be used to reflect the 
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variability of these parameters. While the ∆ is close to zero with little 
variability in healthy controls, it is not a stable measurement in COPD patients, 
Figure 12. 
a)       b)              c) 
 
Figure 12. Within-day (a) and day-to-day (b, c) variability of ∆Xrs. SD: individual standard deviation. 
In COPD, ∆Xrs increases during exacerbations and decreases when the 
exacerbation resolves, and the variability over time of this measurement reflect 
the variability of the disease over time [85]. While the exact value of ∆ varies 
over time in COPD patients with EFLT, COPD patients with ∆ below the 
upper limit of normal defined by healthy subjects have relatively stable 
measurements over time [34, 150]. 
Table 7. Day-to-day variability of the forced oscillation technique (FOT)  
     Measure of variability 
Study Input signal Participants N FOT index SDW CV % 
Timmins[139] SIN COPD 10 Xrs6 0.06 24.4 
       “ “ “ “ Xrs6 insp 0.03 22.0 
       “ “ “ “ ∆Xrs 0.07 87.1 
 Robinson[138] “ Healthy children 34 Xrs6 0.02  
       “ “ Asthma 22 Xrs6 0.02  
Abbreviations as in Table 6.       
 
Inter-subject variability 
Zrs measurements are not normally distributed. For this reason the variability of 
these measurements are commonly reported in interquartile range. In the 
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ECLIPSE/BCCS the 95th or the 5th percentiles were reported. When large inter-
individual variability is found, only extreme values indicate pathology. For this 
reason between-session changes within one individual are usually more valuable 
than any single measurement compared against a reference value.  
 
5.3.4 Associations of EFLT with clinical endpoints 
Expiratory flow limitation is not common in healthy subject, neither at rest, nor 
during heavy exercise [35, 72]. In COPD patients on the other hand, EFLT is 
frequently found. While it is more common in COPD patients with severe airway 
obstruction, it is also found in patients with only moderate airway obstruction 
[68].  
EFLT is functionally relevant as it promotes dynamic hyperinflation and 
increases the positive end-expiratory pressure (PEEP), potentially reducing 
cardiac output [83, 151]. During hyperinflation the work of breathing increases at 
the same time as the diaphragm and other inspiratory muscles have to work at a 
less efficient part of their force-length relationship [81].  
Although many factors contribute to the level of physical activity, exertional 
dyspnea caused by expiratory flow limitation is a major factor in patients with 
COPD [152]. During expiration, there may not be sufficient time for lung 
emptying, leading to a higher end expiratory lung volume. The resulting air-
trapping during activity when ventilatory demands are increased, leads to 
dynamic hyperinflation, which strongly correlates with exertional dyspnea [152]. 
Exertional breathlessness increases when inspiratory muscle activity increases, 
and COPD patients with the lowest ventilatory reserve report the most exertional 
breathlessness for a given activity [153]. Characterizing breathlessness with the 
MMRC in COPD patients, EFLT detected with NEP technique correlates better 
with dyspnoea than spirometry [68, 69], and with FOT, ∆ values far below 
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the established threshold of EFLT, are similar to FEV1 in its ability to identify 
breathlessness.  
Gas exchange abnormalities with a lower diffusion capacity for carbon monoxide 
have been found in COPD patients with EFLT in supine position [154]. 
Orthopnoea in obese subjects may partly be explained by EFLT. Lying flat, obese 
subjects breathe at lower lung volumes, reducing the expiratory reserve volume. 
In morbidly obese, BMI >40 kg/m2, EFLT is frequently found as they are 
breathing close to the residual volume [155]. In obese subjects in contrast to 
COPD patients, EFLT is a positional phenomenon and seldom observed in a 
sitting position [155]. 
In the ECLIPSE/BCCS study COPD patients with EFLT declined significantly in 
6MWD while COPD patients with normal ∆ did not. A third group with 
borderline ∆ measurements, defined as above the upper limit of normal, but 
below the threshold of EFLT also declined significantly. We interpret these 
borderline measurements as showing evidence of EFLT by containing a mixture 
of normal and flow-limited breaths. Physical activity is considerably reduced in 
patients with chronic obstructive pulmonary disease (COPD) and may lead to a 
downward spiral of deconditioning, Figure 13 [156]. 
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Figure 13. Downward spiral of deconditioning caused by tidal expiratory flow limitation with 
concomitant dynamic hyperinflation and exertional dyspnoea. 
The detrimental effect of inactivity is well described. Inactivity is not only 
associated with muscle wasting and a poorer quality of life [157], in COPD low 
levels of physical activity increases the risk of hospitalizations, readmissions, and 
even mortality [158, 159].  
EFLT is prevalent during acute exacerbations of COPD. As exacerbations 
resolves, ∆Xrs has been shown to decrease [85]. In the ECLIPSE study, evidence 
of EFLT with ∆ ≥ULN was a significant predictor for increased risk of 
exacerbations, and these COPD patients had a shorter time to first exacerbation 
and first hospitalization. COPD patients with evidence of EFLT and a FEV1 
<50% predicted also had a significantly higher risk of dying. 
 
5.3.5 Implications 
Since our report on reference values in asymptomatic elderly, a larger study of 
whole-breath oscillatory mechanics have been published in adults of advanced 
Reduced 
physical activity 
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age which should be preferred due to larger sample size [35, 66]. However, the 
reference equations generated in the BELH study are presently the only normal 
values for partitioned within breath oscillatory indices [35].  
The BELH study demonstrates that high ∆ measurements were rare in 
asymptomatic elderly. At the same time, a significant risk of over-diagnosing 
COPD in elderly never-smokers was found when the fixed 0,7 FEV1/FVC ratio 
was used. 35% of these very old subjects had a lower ratio [27]. While it is 
acknowledged that the fixed FEV1/FVC ratio leads to a more frequent diagnose 
of COPD in the elderly than using the LLN of the FEV1/FVC ratio [160, 161], 
characterizing the bottom 5% of the healthy population as abnormal, the GOLD 
guidelines favors the fixed ratio over the LLN due to simplicity and 
independence of reference values [1]. In elderly characterized as having COPD 
by the fixed ratio where the clinical suspicion still is low, the present studies 
indicate that abnormal ∆ measurement should strengthen the diagnose of 
COPD.  
Although the Milano study and the previous study by Hellinckx et al were too 
small to exclude existence of systemic differences in pulmonary reactance 
measured by different input signal waveforms, both studies found very similar 
Xrs measurements [37, 47].  The studies support that the threshold of EFLT 
derived using sinusoidal pressure oscillations may also be used for PRN or 
impulse oscillations devices, and that the upper limit of normal of ∆derived 
with impulse oscillations may be used for devices using sinusoidal pressure 
oscillations or PRN. 
Most FOT parameters have good between-test reproducibility. Within-breath Xrs 
measurements have a higher variability in COPD patients. We interpret this to be 
caused by dynamic regulation of the end-expiratory lung volume in order to 
prevent EFLT. When some breaths are flow-limited and others not, the ∆Xrs will 
vary from breath to breath. The within-day variability of ∆Xrs is acceptable with 
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an intra-class correlation coefficient of 0.94 (Table 6) [139]. The day-to-day 
variability is large for ∆.  
Differences in symptoms and clinically relevant outcomes were found in COPD 
patients with baseline ∆ beyond the upper limit of normal. ∆ identifies 
breathlessness, defined as having a MMRC dyspnoea scale score ≥2. In addition, 
there were significant differences with regards to decline in 6-minute walk 
distance, exacerbations, and also mortality in COPD patients with ∆ ≥ULN 
compared with COPD patients with ∆ comparable with healthy controls. As 
with airway obstruction in asthma, with ∆ ≥ULN may not be present at any 
given evaluation of a COPD patient. Patients with EFLT, or ∆ ≥ULN have a 
worse lung mechanics than is evident from spirometry measurements alone.  
EFLT have mechanical, muscular, cardiovascular, symptomatic, and prognostic 
consequences. With FOT, EFLT is easily determined. The feasibility of FOT 
measurements makes these measurements particularly useful in COPD patients 
unable to perform spirometry. We suggest borderline measurements of ∆ 
indicating evidence of EFLT, may be used as marker identifying a subgroup of 
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6. Conclusions 
• Healthy controls as well as elderly without respiratory complaints 
generally have very low ∆. FOT defined EFLT is not common in 
healthy elderly. 
• Impulse oscillation forcing signals overestimates Rrs5 compared with 
PRN and sinusoidal pressure oscillations. Reactance measurements are 
similar using different devices with no systemic differences, 
supporting the use of the same threshold when the ULN and EFLT are 
estimated using devices with different forcing signals.  
• Most FOT measurements have good between-test reproducibility.  The 
variability increases with increasing measurements. Although EFLT 
may vary from breath-to-breath, variability of ∆ is acceptable when 
measured over multiple breaths. The day-to-day variability of ∆ is 
large. 
• ∆ is associated with dyspnoea and clinically relevant outcomes, 
such as decline in the 6-minute walk test, exacerbations, 
hospitalizations, and death.  
• We suggest that ∆ may be used as a marker to identify a subgroup 
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7. Perspectives 
The present thesis facilitates the use of FOT by supplying normal values in 
elderly, comparing the agreement between different forcing signals, and by 
examining the variability. Finally, we explored the association of ∆ with 
dyspnea and clinically relevant outcomes, such as decline in walking distance, 
exacerbations, and death. Suggestions for further research are: 
• Reference values in elderly should have an expiration date. Updates are 
necessary to capture changes in occupational exposure to dust and noxious 
particles as well as different smoking habits between generations.  
• Reference studies where the study population is examined by several 
different input forcing signals are needed if device independent reference 
equations are to be retrieved. 
• The agreement between the ∆ and the NEP technique, has not been 
resolved, nor has IC maneuvers been performed in relation to the ∆ 
measurements. 
• The clinical importance of ∆ needs further research. 
o Patients unable to perform spirometry could benefit from other 
means of evaluation, i.e. patients on respirators, the cognitive 
impaired, and children. 
o Can ∆ be used to set PEEP in ventilators, and would algorithms 
using ∆ have advantage over algorithms using flow? Can we 
use this parameter to evaluate treatment effects of bronchodilators 
in patients on mechanical ventilation? 
o Do patients with ∆ >ULN benefit from pulmonary 
rehabilitation? Can loss of walking distance in the 6MWT be 
prevented? Does physical exercise improve ∆ and/or the 
tendency of flow-limited breaths? 
 
 




The total number of subjects in the Phase II age-, sex-, and smoking history 
random subsample of the BELH study was 319. From this sample only the 208 
subjects who reported to be never-smokers were called in for further testing, not 
319 as stated. 
Throughout the paper the measuring unit of the FOT parameters: Rrs, Xrs and 
∆Xrs are reported as kPa·L-1·s-1. The correct measuring unit is kPa·s·L-1. 
Paper II 
Each individual part of the 6 part figure, Fig. 3 contains several graphs, a 
scatterplot showing the relationship between sinusoidal and impulse oscillation 
measurements, a Deming regression line with it’s confidence intervals, and 2 
dotted lines illustrating the expected biological variation derived from the 2.5 and 
the 97.5 percentile line derived from the 425 COPD patients in the Bergen 
Cohort of the ECLIPSE study. 
The dotted lines representing the 2.5 and the 97.5 percentile lines have been 
misplaced and are too narrow in figure 3d-f. The correct position of the 
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Ikke bruk for lang tid til å tenke over hva du skal svare.
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ST. GEORGE SPØRRESKJEMA OM LUFTVEISPROBLEMER DEL 1
Spørsmål om hvor mye lungeplager du har.












[1] [2] [4] [5]
1. Har jeg hostet: q q q q
2. Har jeg hostet opp slim: q q q q
3. Jeg er tungpusten: q q q q
4. Jeg har anfall med piping i brystet: q q q q
5. Hvor mange anfall med lungeplager hadde du i løpet
av det siste året?
3 eller flere dager b[1]
1 eller 2 dager b[3]
Ingen perioder b[5]
6. Hvor ofte har du hatt gode dager (med lite lungeplager)?
Ingen gode dager b[1]
noen gode dager b[?]
de fleste dage er god b[4]
Hver dag er god b[5]
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ST. GEORGE SPØRRESKJEMA OM LUFTVEISPROBLEMER DEL 2
8. Hvordan vil du beskrive din lungetilstand?
Sett ett kryss:
Forårsaker svært mange problemer eller er det viktigste problemet jeg har b[1]
Det gir meg noen få problemer b[3]
Det gir meg ingen problemer b[4]
9. Spørsmål om hvilke aktiviteter som vanligvis gjør deg tungpusten
For hver setning, vennligst sett kryss i ruten som passer best for din situasjon nå for tiden:
Riktig Galt
[T] [F]
Vaske deg eller kle på deg q q
Gå omkring hjemme q q
Spasere utendørs på flatmark q q
Gå opp en trapp, én etasje q q
Gå i motbakke q q
10. Noen flere spørsmål om din hoste og tunge pust.
For hver setning, vennligst sett kryss i ruten som passer best for din situasjon nå for tiden:
Riktig Galt
[T] [F]
Det gjør vondt når jeg hoster q q
Min hoste gjør meg sliten q q
Jeg er tung i pusten når jeg snakker q q
Jeg er tung i pusten når jeg bøyer meg q q
Min hoste eller tunge pust forstyrrer søvnen min q q
Jeg blir fort utslitt q q
NO:NOR (Norway/Norwegian)
8
Final - 12 DEC 05CONFIDENTIAL
Protocol Identifier Subject Identifier Visit Description
SCO104960 {{{{{{} Visit 1
*SCO104960* Page*104* 104
ST. GEORGE SPØRRESKJEMA OM LUFTVEISPROBLEMER DEL 2
11. Spørsmål om annen innvirkning på deg av dine lungeplager.
For hver setning, vennligst sett kryss i ruten som passer best for din situasjon nå for tiden:
Riktig Galt
[T] [F]
Min hoste eller tunge pust gjør meg pinlig berørt når jeg er ute blant folk q q
Mine luftveisproblemer sjenerer familie, venner eller naboer q q
Jeg blir redd eller får panikk når jeg får en følelse av å ikke få nok luft q q
Jeg føler at jeg ikke har kontroll over mine luftveisproblemer q q
Jeg har blitt svekket eller ufør av mine luftveisproblemer q q
Mosjon er ikke trygt for meg q q
Alt føles altfor anstrengende q q
12. Dette er spørsmål om hvordan dine gjøremål kan bli påvirket av pusten din.
For hvert spørsmål, vennligst sett kryss i ruten som passer for din situasjon, med tanke på pusten:
Riktig Galt
[T] [F]
Jeg bruker lang tid på å vaske meg eller kle på meg q q
Jeg kan ikke bade eller dusje, eller må bruke lang tid på det q q
Jeg går langsommere enn andre folk, eller må stanse for å hvile meg q q
Husarbeid og andre lignende gjøremål tar lang tid, eller jeg må stanse for å
hvile meg
q q
Hvis jeg går opp trappa en etasje, må jeg gå langsomt eller stanse q q
Hvis jeg skynder meg eller går fort, må jeg stanse eller gå saktere q q
Pusten min gjør det vanskelig for meg å gjøre ting som å gå opp bakker, bære
ting opp trapper, utføre lett hagearbeid som luking, danse, bowle eller spille golf q q
Pusten min gjør det vanskelig for meg å gjøre slike ting som å bære tungt,
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ST. GEORGE SPØRRESKJEMA OM LUFTVEISPROBLEMER DEL 2
13. Vi vil gjerne vite hvordan dine luftveisproblemer vanligvis påvirker ditt daglige liv.
For hvert spørsmål, vennligst sett kryss i ruten som passer for din situasjon, med tanke på pusten:
Riktig Galt
[T] [F]
Jeg kan ikke drive med sport eller idrett q q
Jeg kan ikke gå ut på underholdningstilbud eller dra hjemmefra for å drive med
fritidsaktiviteter
q q
Jeg kan ikke gå ut for å handle q q
Jeg kan ikke gjøre husarbeid q q
Jeg kan ikke bevege meg langt vekk fra stolen eller senga q q
14. Kan du nå sette et kryss (og bare ett) for det du synes best beskriver hvorledes dine
luftveisproblemer påvirker deg:
De forhindrer meg ikke fra noe av det jeg ønsker å gjøre b[1]
De forhindrer meg fra en eller to ting jeg ønsker å gjøre b[2]
De forhindrer meg fra mesteparten av det jeg ønsker å gjøre b[3]
De forhindrer meg fra alt jeg ønsker å gjøre b[4]
Takk for at du ville fylle ut dette spørreskjemaet.
Vennligst kontroller at du har besvart alle spørsmålene.
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ATS-DLD-78-A
Disse spørsmålene omhandler stort sett brystkassen din.
1. SYMPTOMER
1A.Hoster du vanligvis?
Note: Tell et tilfelle av hosting første gang du røyker eller første gang du går
utendørs. Unnta kremting for å rense halsen.
Hvis NEI, FORTSETT med spørsmål 1C.
[Y]bJa [N]bNei
[U]bVet ikke








1D).Hoster du vanligvis i det hele tatt i løpet av resten av dagen eller om natten? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på ALLE de ovenstående (1A, 1B, 1C og 1D), skal du merke av
for "Gjelder ikke" og FORTSETTE med spørsmål 2.A.
Hvis du svarte JA på MINST ETT av ovenstående (1A, 1B, 1C eller 1D), BESVAR
følgende spørsmål:
[X]bGjelder ikke
1E).Hoster du vanligvis som dette de fleste dagene i minst tre måneder etter
hverandre i løpet av året?
[Y]bJa [N]bNei
[U]bVet ikke
1F).I hvor mange år har du hatt denne hosten?  {{} År
[U]bVet ikke
2. OPPHOSTET SLIM
2A.Får du vanligvis opp slim fra brystet?
Note: Tell antall tilfeller av opphosting av slim første gang du røyker eller første
gang du går utendørs. Ikke tell slim fra nesen. Tell slim som svelges.
Hvis NEI, FORTSETT med spørsmål 2C.
[Y]bJa [N]bNei
[U]bVet ikke
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2D.Får du vanligvis opp slim i det hele tatt i løpet av resten av dagen eller om natten? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på ALLE de ovenstående (2A, 2B, 2C og 2D), skal du merke av
for "Gjelder ikke" og FORTSETTE med spørsmål 3.A.
Hvis du svarte JA på MINST ETT av ovenstående (2A, 2B, 2C eller 2D), BESVAR
følgende spørsmål:
[X]bGjelder ikke
2E.Får du vanligvis opp slim på denne måten de fleste dager i minst tre måneder
etter hverandre i løpet av året? [Y]bJa [N]bNei
[U]bVet ikke
2F. I hvor mange år har du hatt problemer med opphostet slim?   {{} År
[U]bVet ikke
2G.Har du hatt perioder eller episoder med (økt1) hosting og opphosting av slim som
har vart i minst tre uker hvert år?
1For enkeltpersoner som vanligvis hoster og/eller hoster opp slim.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 2G, FORTSETT med spørsmål 3.A.
Hvis du svarte JA på 2G, BESVAR følgende spørsmål:
2H.Hvor lenge har du hatt minst én slik episode i året?   {{} År
[U]bVet ikke
3. HVESING
3A.Hører du noen gang hvesing eller piping i brystet? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 3A, FORTSETT med DEL 4 (brystforkjølelser og
brystsykdommer). Hvis du svarte JA på 3A, BESVAR følgende spørsmål:
3B.Har brystet ditt noen gang hvese- eller pipelyd... Merk av for det beste svaret for hvert punkt:
1. Ved forkjølelse? [1]bAldri [2]bAv og til [3]bDe fleste
2. Når du ikke er forkjølet? [1]bAldri [2]bAv og til [3]bDe fleste
3. Ved trening eller anstrengelse? [1]bAldri [2]bAv og til [3]bDe fleste
4. Ved utsettelse for pollen? [1]bAldri [2]bAv og til [3]bDe fleste
5. Etter at du har tatt aspirin? [1]bAldri [2]bAv og til [3]bDe fleste
6. Ved utsettelse for støv? [1]bAldri [2]bAv og til [3]bDe fleste
7. Ved utsettelse for dunster? [1]bAldri [2]bAv og til [3]bDe fleste
8. Ved utsettelse for spray? [1]bAldri [2]bAv og til [3]bDe fleste
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3C.Når oppstod hvesingen eller pipelydene sist? Merk av for én: [1]bDen siste uken
[2]bFor en måned siden
[3]bFor mer enn en
måned siden
3D.I hvor mange år har du hatt det?   {{} År
[U]bVet ikke
3E.Har du noen gang hatt tilfeller av hvesing hvor du har kjent deg kortpustet? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI, på spørsmål 3.E. FORTSETT med spørsmål 4.A.
Hvis du svarte JA på 3.E, BESVAR følgende spørsmål:
3F.Hvor gammel var du da du hadde ditt første anfall av denne typen?   {{} år gammel
[U]bVet ikke
3G.Har du hatt minst to slike episoder? [Y]bJa [N]bNei
[U]bVet ikke
3H.Har du noensinne hatt behov for medisiner eller behandling for disse tilfellene? [Y]bJa [N]bNei
[U]bVet ikke
4. HOSTING FRA BRYSTET OG SYKDOM I BRYSTET
4A.Hvis du blir forkjølet, er det vanligvis i brystet?




4B.Har du i løpet av de siste tre årene hatt sykdom i brystet som har forhindret deg




Hvis du svarte NEI på spørsmål 4.B, FORTSETT med spørsmål 5.A.
Hvis du svarte JA på 4.B, BESVAR følgende spørsmål:
4C.Hostet du opp slim under noen av disse tilfellene av sykdom i brystet? [Y]bJa [N]bNei
[U]bVet ikke
4D.I løpet av de siste tre årene, hvor mange slike sykdomstilfeller med (økt)






Final - 13 DEC 05CONFIDENTIAL
Protocol Identifier Subject Identifier Visit Description




5A.Hadde du lungeproblemer før du var 16 år gammel? [Y]bJa [N]bNei
[U]bVet ikke




Hvis du svarte NEI på spørsmål 5.B., FORTSETT med spørsmål 5.C.
Hvis du svarte JA på 5.B, BESVAR følgende spørsmål:
1. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke




Hvis du svarte NEI på spørsmål 5.C., FORTSETT med spørsmål 5.D.
Hvis du svarte JA på 5.C, BESVAR følgende spørsmål:
1. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke




Hvis du svarte NEI på spørsmål 5.D., FORTSETT med spørsmål 5.E.
Hvis du svarte JA på 5.D, BESVAR følgende spørsmål:
1. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke
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ATS-DLD-78-A (forts.)
5. TIDLIGERE SYKDOMSTILFELLER (forts.)
5.E.Lungebetennelse (inkludert bronkittlungebetennelse)? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 5.E., FORTSETT med spørsmål 5.F.
Hvis du svarte JA på 5.E, BESVAR følgende spørsmål:
1. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke




Hvis du svarte NEI på spørsmål 5.F., FORTSETT med spørsmål 5.G.
Hvis du svarte JA på 5.F, BESVAR følgende spørsmål:
1. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke
2. Hvor gammel var du da det begynte? {{} år gammel
[U]bVet ikke
5G.Har du noensinne hatt astma? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 5.G., FORTSETT med spørsmål 5.H.
Hvis du svarte JA på 5.G, BESVAR følgende spørsmål:
1. Har du det fremdeles? [Y]bJa [N]bNei
[U]bVet ikke
2. Ble det bekreftet av en lege? [Y]bJa [N]bNei
[U]bVet ikke
3. Hvor gammel var du da det begynte? {{} år gammel
Vet ikke
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ATS-DLD-78-A (forts.)
5. TIDLIGERE SYKDOMSTILFELLER (forts.)
5. Har du noensinne vært innlagt på sykehus natten over for astma? [Y]bJa [N]bNei
[U]bVet ikke




5.H Har du noensinne hatt noen form for sykdom i brystet? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 5.H., FORTSETT med spørsmål 5.I.
Hvis du svarte JA på 5.H., angi: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5.I. Har du noensinne hatt noen form for brystoperasjon? [Y]bJa [N]bNei
Hvis du svarte NEI på spørsmål 5.I., FORTSETT med spørsmål 5.J.
Hvis du svarte JA på 5.I., angi: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
5.J.Har du noensinne hatt noen form for skader på brystet? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 5.J., FORTSETT med spørsmål 5.K.
Hvis du svarte JA på 5.J., angi: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _




Hvis du svarte JA, hvor mange ganger? {{} ganger




Hvis du svarte JA, hvor mange ganger? {{} ganger
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6A.Har du noensinne jobbet heltid (minst 30 timer i uken) i minst seks måneder? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 6.A., FORTSETT med spørsmål 7.A.
Hvis du svarte JA på 6.A, BESVAR følgende spørsmål:
6B.Har du noensinne arbeidet i minst ett år på en støvfylt arbeidsplass?
Hvis du svarte JA på 6.B.,
[Y]bJa [N]bNei
[U]bVet ikke
1. Angi jobb/bransje: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
{{} Samlet antall år
jobbet
2. Var utsettelsen for støv? Merk av for én: [1]bMild
[2]bModerat
[3]bAlvorlig
6C.Har du noensinne vært utsatt for gass eller kjemiske dunster i jobben din?
Hvis du svarte JA på 6.C.,
[Y]bJa [N]bNei
[U]bVet ikke
1. Angi jobb/bransje: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
{{} Samlet antall år
jobbet




7.A.Har du noensinne røykt sigaretter?
Note: ’Nei’ betyr mindre enn 20 pakker sigaretter eller 340 g (eller 12 oz) tobakk
i hele livet eller mindre enn én sigarett om dagen i ett år.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 7.A., FORTSETT med spørsmål 7.B.
Hvis du svarte JA på 7.A, BESVAR følgende spørsmål:
1. Røyker du for tiden sigaretter (per 1 måned siden)? [Y]bJa [N]bNei
[U]bVet ikke
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3. Hvis du har sluttet helt å røyke sigaretter, hvor gammel var du da du
sluttet?
Merk av her hvis du fremdeles røyker sigaretter
{{} I hvilken alder sluttet du?
[U]bVet ikke
b
4. Hvor mange sigaretter røyker du nå per dag? {{} sigaretter/dag
[U]bVet ikke
5. Når du tar i betraktning hele tiden du røykte, hvor mange sigaretter om
dagen røykte du i gjennomsnitt?
{{} sigaretter/dag
[U]bVet ikke












7.B.Har du røykt sigaretter i løpet av det siste døgnet? [Y]bJa [N]bNei
[U]bVet ikke
7.C.Angi om foreldrene dine noensinne var sigarettrøykere...
1. Mor? [Y]bJa [N]bNei
[U]bVet ikke
2. Far? [Y]bJa [N]bNei
[U]bVet ikke
7.D.Har du noensinne røykt pipe regelmessig?
Note: ’Ja’ betyr mer enn 340 g (eller 12 oz) tobakk i løpet av livet.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 7.D., FORTSETT med spørsmål 7.E.
Hvis du svarte JA på 7.D, BESVAR følgende spørsmål:
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1. Hvor gammel var du da du begynte å røyke pipe regelmessig? {{} år gammel
[U]bVet ikke
2. Hvis du har sluttet helt å røyke pipe, hvor gammel var du da du sluttet?
Merk av her hvis du fremdeles røyker pipe
{{} I hvilken alder sluttet du?
[U]bVet ikke
b
3. Når du tar i betraktning hele tiden du røykte pipe, hvor mye pipetobakk i
uken røykte du i gjennomsnitt?




4. Hvor mye pipetobakk røyker du nå?








7.E.Har du noensinne røykt sigarer regelmessig?
Note: ’Ja’ betyr mer enn én sigar i uken i et år.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 7.E., FORTSETT med spørsmål 7.F.
Hvis du svarte JA på 7.E, BESVAR følgende spørsmål:
1. Hvor gammel var du da du først begynte å røyke sigarer regelmessig?
{{} år gammel
[U]bVet ikke
2. Hvis du har sluttet helt å røyke sigarer, hvor gammel var du da du sluttet?
Merk av her hvis du fremdeles røyker sigarer
{{} I hvilken alder sluttet du?
[U]bVet ikke
b
3. Når du tar i betraktning hele tiden du røykte sigarer, hvor mange sigarer i
uken røykte du i gjennomsnitt?
{{} Sigarer i uken
[U]bVet ikke
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7.F.Har du noensinne røykt sigarilloer regelmessig?
Note: ’Ja’ betyr mer enn én sigarillo i uken i et år.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 7.F., FORTSETT med spørsmål 7.G.
Hvis du svarte JA på 7.F, BESVAR følgende spørsmål:
1. Hvor gammel var du da du først begynte å røyke sigarilloer regelmessig?
{{} år gammel
[U]bVet ikke
2. Hvis du har sluttet helt å røyke sigarilloer, hvor gammel var du da du sluttet?
Merk av her hvis du fremdeles røyker sigarilloer




3. Når du tar i betraktning hele tiden du røykte sigarilloer, hvor mange sigarilloer
i uken røykte du i gjennomsnitt?
{{} i uken
[U]bVet ikke
4. Hvor mange sigarilloer i uken røyker du nå? {{} i uken
[U]bVet ikke




7.G.Har du noensinne vært utsatt for tobakksrøyk fra andre i omgivelsene dine i
løpet av de siste 24 timene?
Note: Ikke inkluder deg selv.
[Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 7.G., skal du angi hvor mye tobakksrøyk du har blitt utsatt
for fra andre:
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7.H.Er det noen andre i hjemmet ditt enn deg som røyker regelmessig?
Note: Enten de bor hos deg eller ikke. Ikke inkluder deg selv.
[Y]bJa [N]bNei
[U]bVet ikke
7.I. Røykte noen andre enn deg regelmessig i hjemmet ditt under oppveksten din (før
du fylte 18 år)?




Angi om en lege noensinne har fortalt deg at du hadde noen av følgende sykdommer
ved å svare på følgende spørsmål:
8.A.Hjerteproblemer? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 8.A., FORTSETT med spørsmål 8.B.
Hvis du svarte JA på 8.A, BESVAR følgende spørsmål:




8.B.Høyt blodtrykk (hypertensjon)? [Y]bJa [N]bNei
[U]bVet ikke
Hvis du svarte NEI på spørsmål 8.B., FORTSETT med spørsmål 8.C.
Hvis du svarte JA på 8.B, BESVAR følgende spørsmål:
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8.H.Osteoporose eller ’tynne’ bein? [Y]bJa [N]bNei
[U]bVet ikke
8.I. Osteoartrose? [Y]bJa [N]bNei
[U]bVet ikke
8.J.Revmatisk artrose? [Y]bJa [N]bNei
[U]bVet ikke




Hvis du svarte NEI på spørsmål 8.L., FORTSETT med spørsmål 8.M.
Hvis du svarte JA på 8.L, BESVAR følgende spørsmål:
1. Har du type 1-sukkersyke? [Y]bJa [N]bNei
[U]bVet ikke
2. Har du type 2-sukkersyke? [Y]bJa [N]bNei
[U]bVet ikke




Final - 13 DEC 05CONFIDENTIAL
Protocol Identifier Subject Identifier Visit Description




8.N.Gastroøsofageal refluks / halsbrann? [Y]bJa [N]bNei
[U]bVet ikke
8.O.Depresjon som må behandles? [Y]bJa [N]bNei
[U]bVet ikke
8.P.Angst eller panikkanfall? [Y]bJa [N]bNei
[U]bVet ikke
9. SOSIOØKONOMISK STATUS
9.A.Hva er det siste året eller graden av skolegang du har fullført?
Merk av for bare ett av følgende alternativer:
[1]bIngen grunnskole eller ikke fullført
[2]bFullført grunnskolen
[3]bNoe videregående skole
[4]bFullført 3-årig videregående skole
[5]bTeknisk fagskole / annen skolegang under høyskolenivå
[6]bUniversitets-/høyskolegrad
[7]bHøyere grad fra universitet/høyskole
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MRC-DYSPNÉSKALA
Oppgi det ene svaret som gjelder for deg.
Merk av for bare én:
[0]b Jeg blir bare andpusten når jeg trener hardt.
[1]b Jeg blir kortpustet når jeg skynder meg på flat mark eller når jeg går opp en slakk bakke.
[2]b Jeg går saktere enn folk på samme alder som meg på flat mark på grunn av andpustenhet, eller jeg måstanse opp for å ta en pust i bakken når jeg går i mitt eget tempo på flat mark.
[3]b
Jeg stanser for å ta en pust i bakken etter å ha gått omtrent 100 meter eller etter noen få minutter på flat
mark.
[4]b Jeg blir for andpusten til å gå ut av huset eller jeg blir andpusten når jeg kler av eller på meg.
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• The MRC Dyspnea Scale is to be completed by the study subject.
• If the subject’s perception is not quite Grade 2 or if the subject is somewhat unsure if their breathlessness is Grade 2,
have the subject rate Grade 2.
• If the subject insists on rating less than Grade 2, even if you have no doubts that the subject should be rating at
or above Grade 2, the subject’s rating of less than Grade 2 must stand.
GRADERINGSBESKRIVELSER
Gradering 0 Ikke plaget unntatt under anstrengende trening (denne graden er vanlig for eldre enkeltpersonersom er I FORM).
Gradering 1 Plaget når forsøkspersonen skynder seg på flat mark eller opp en slakk bakke (denne graderingener vanlig for de FLESTE SUNNE OG FRISKE enkeltpersoner).
Gradering 2
Går saktere enn folk i samme alder eller stanser for å ta en pust i bakken ved gange på flat mark
(forsøkspersonen må stanse for å ta en pust etter å ha gått om lag halvannen kilometer eller etter
å ha gått i OMTRENT 30 MINUTTER).
Gradering 3 Stanser for å ta en pust i bakken etter å ha gått omtrent 100 meter eller etter noen få minutter påflat mark.





Visitt nr. Dato for undersøkelse 
(dd.mm.yyyy)
Fødselsdato (dd.mm.yyyy)

















Hvis annen rase, beskriv:
Antall søsken (ekskl. deg selv):
Deltakers plassering i søsken- 
flokken (førstefødt = 1)
OPPFØLGING AV DELTAKERE FRA GENKOLS OG 
HORDALANDSSTUDIEN 2006 - 2009






Søsken i GenKOLS? Ja Nei




Hvis ja, GenKOLS id#
98
B. Sykdommer i familien
Både nåværende og tidligere sykdommer medregnes.
a) Far Ja Nei Ukjent
1. KRONISK BRONKITT
Antall barn med sykdommen
2. EMFYSEM
b) Mor Ja Nei Ukjent
d) Barn Ja Nei Ukjent
Antall søsken med sykdommen
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
c) Søsken Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
3. ASTMA
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
4. ATOPISK DERMATITT
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
5. HØYSNUE
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen




a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
7. ANNEN LUNGESYKDOM
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
Hvilke(n) lungesykdom(mer)?
8. ANGINA PECTORIS / KORONAR HJERTESYKDOM
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
9. ANNEN HJERTESYKDOM
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
Hvilke(n) hjertesykdom(mer)?
10. BEHANDLINGSTRENGENDE HØYT KOLESTEROL
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
11. BEHANDLINGSTRENGENDE HØYT BLODTRYKK
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
100
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
12. HJERNESLAG
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
13. DIABETES TYPE 1
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
14. DIABETES TYPE 2
a) Far Ja Nei Ukjent b) Mor Ja Nei Ukjent
Antall søsken med sykdommen Antall barn med sykdommen
c) Søsken Ja Nei Ukjent d) Barn Ja Nei Ukjent
C. Egne tidligere og nåværende sykdommer
Tidligere innlagt på sykehus? Ja Nei
Obstruktiv Nei Ja, før Ja, nå
2. LUNGESYKDOM
Sarkoidose Nei Ja, før Ja, nå
Lungefibrose Nei Ja, før Ja, nå Lungetuberkulose Nei Ja, før Ja, nå




Angina pectoris/koronar Nei Ja Hjertesvikt Nei Ja
3. KOLS
Årstall for sykdomsdebut KOLS
Hvis deltaker har KOLS:
Antall eksaserbasjoner siste 12 mnd.
For eksaserbasjon 1, registrer:
For eksaserbasjon 2, registrer:
For eksaserbasjon 3, registrer:
For eksaserbasjon 4, registrer:





































Rytmeforstyrrelse Nei Ja, før Ja, nå Hypertensjon Nei Ja, før Ja, nå
Hjerneslag Nei Ja
Lunge Nei Ja, før Ja, nå Tarm Nei Ja, før Ja, nå
5. KREFT
Bryst Nei Ja, før Ja, nå Prostata Nei Ja, før Ja, nå
Annen kreftsykdom Nei Ja, før Ja, nå
Hvilken kreftsykdom?
6. DIABETES
Diabetes type 1 Nei Ja Diabetes type 2 Nei Ja
OSAS Nei Ja, før Ja, nå
7. OBSTRUKTIVT SØVN APNOE SYNDROM
8. ALLERGIER
Atopisk dermatitt Nei Ja, før Ja, nå Høysnue Nei Ja, før Ja, nå
Matallergi Nei Ja, før Ja, nå Medikamentallergi Nei Ja, før Ja, nå
Hvilke(t) medikament(er)?
Tidligere anafylaksi Nei Ja
11. ORGANSVIKT
Nyresvikt Nei Ja Leversvikt Nei Ja





Skade / traume / forgiftning Nei Ja, før Ja, nå
Hva / hvilken?
12. BEHANDLINGSTRENGENDE PSYKISK LIDELSE
Depresjon Nei Ja, før Ja, nå Psykose Nei Ja, før Ja, nå
13. HEMATOLOGISK SYKDOM
DVT Nei Ja, før Ja, nå Lungeemboli Nei Ja, før Ja, nå
14. ANNEN SYKDOM
Annen sykdom Nei Ja, før Ja, nå
D. Bruk av faste medikamenter
Bruker medisiner fast Nei Ja





Har tatt influensavaksine sist sesong Nei Ja























Røyker du for tiden?
Nei, har aldri røykt Nei, men røykte før





Aldri røykt defineres som mindre enn en 
sigarett daglig i ett år
Hvis ikke deltaker vet dag/mnd for start og/eller slutt, la det stå åpent, men prøv å tvinge frem 
et årstall - eventuelt hjelp til med å regne ut fra alder på start- og/eller slutt-tidspunkt
Har du hatt perioder der du ikke har røykt? I så fall, hvor mange røykfrie år utgjør 
disse periodene til sammen?
Hvis du røyker eller har røykt daglig, røyker/røykte du sigaretter daglig?
Ja, fabrikkfremstilte Ja, håndrullede Nei, ikke sigaretter
Hvis du røyker/røykte fabrikkfremstilte sigaretter: hvor mange sigaretter 
røyker/røykte du daglig?
Hvis du røyker/røykte håndrullede sigaretter: hvor mange pakker (50 g) 
tobakk røyker/røykte du pr. uke? (husk å punsje med 1 desimal, slik at 
f. eks 3 pakker punsjes 3,0)
Bruker snus:
Nei Ja, før Ja, nå
Bruker nikotin substitusjon:
Nei Ja, før Ja, nå
F. Status presens
Klokkeslett Puls


















Systolisk grad 2 Systolisk grad 3 Systolisk grad 4 Diastolisk
Auskultasjon pulm.:










Hvis knatrelyder, lokalisering av disse (kryss alle som gjelder):
Høyre Venstre
Bruker pasienten kontinuerlig oksygen? Ja Nei
Hvis ja, oksygentilførsel siste 30 minutter før prøvetaking (l/min):
Lege (4kode):
Tatt nasopharynx prøve til Virus Ag påvisning? Nei Ja
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Abstract
Introduction: A new application for the forced oscillation technique (FOT) has
been described by Dellaca et al. using sinusoidal pressure variations at 5 Hz to
detect expiratory flow limitation by measuring the within-breath reactance
[termed difference between inspiratory and expiratory X5 (DX5)]. Few studies
have been performed on respiratory phase differences in the elderly.
Objective: Our aim was to present reference values for within-breath impedance
measurements and to examine how the earlier mentioned method performs in a
study population of asymptomatic elderly.
Methods: An age- and sex-stratified random sample was drawn from the elderly
population of Bergen, Norway. Among the healthy non-smoking responders from
a postal questionnaire study, 148 were selected to perform FOT measurements
using an impulse oscillometry system (IOS). Seventy five of these participants had
a normal spirometry and were able to perform at least two valid FOT measure-
ments. Predictive equations for men and women were created for FOT parameters
by linear multiple regression analysis. DX5 was calculated from the within-breath
variation of reactance at 5 Hz.
Results/Conclusion: This study presents reference values for whole-breath and
within-breath impedance parameters in asymptomatic elderly aged >70 years using
the IOS method. We found higher resistance measurements than what is reported
in previous studies and significantly larger frequency dependence.
Please cite this paper as: Aarli BB, Eagan TML, Ellingsen I, Bakke PS and Hardie JA.
Reference values for within-breath pulmonary impedance parameters in asympto-
matic elderly. Clin Respir J 2012; ••: ••–••. DOI:10.1111/j.1752-699X.2012.00312.x.
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The forced oscillation technique (FOT) allows us to
measure airway mechanics, including resistance and
reactance, non-invasively during normal tidal breath-
ing. In contrast with most other pulmonary function
tests (PFTs), the FOT does not use the respiratory
muscles as the source of force but instead superim-
poses flow oscillations to spontaneous breathing by
the means of an external loudspeaker (1, 2). The
advantages of this technique are that it does not require
complex panting maneuvers, it is less subject-
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dependent and it can be applied to patients who for
various reasons are unable to cooperate during forced
spirometry or plethysmography. In the elderly, it has
been found to have a higher feasibility rate than
spirometry, especially in the presence of cognitive
impairment, and it provides us with information about
lung mechanics that cannot be obtained using spirom-
etry alone (3, 4). Consequently, FOT could provide a
valuable tool for evaluation of subjects unable to
perform other PFT. Recently, several studies have
focused on within-breath FOT variation. In chronic
obstructive pulmonary disease (COPD) patients, a sig-
nificant difference has been observed between inspira-
tory and expiratory reactance (5, 6). This is not present
in asthmatics or healthy subjects during normal tidal
breathing but manifests at closing volume if end-
expiratory reactance is measured during slow vital
capacity maneuvers (7). These within-breath reactance
differences are believed to be caused by choke points of
collapsing airways in expiration. As a further applica-
tion of this phenomenon, Dellaca et al. have demon-
strated that it is possible to accurately detect expiratory
flow limitation (EFL) by measuring the within-breath
difference of reactance using sinusoidal pressure vari-
ations at 5 Hz in COPD patients (2, 8, 9). Few studies
have been performed on within-breath FOT measure-
ments (i.e. inspiration vs expiration), and normal
values for these parameters are yet to be established.
In 2003, the European Respiratory Society (ERS)
published recommendations for FOT measurements
in a task force report where reference studies on adults
are summarized (10). Guo et al. later published the first
FOT reference values for older subjects (11). These
recommendations and reference values were based on
the pseudorandom noise (PRN) method of FOT. The
impulse oscillometry system (IOS) applies short FOT
pressure pulses rather than continuous PRN. The tech-
nique has a better time resolution than PRN, which is
particularly useful when analyzing intrabreath varia-
tion of airway impedance (1). However, the IOS may
render higher measures of resistance than PRN FOT at
lower frequencies, as shown in the comparison study
performed by Hellinckx et al. (12). Hellinckx et al. sug-
gested that the IOS overestimated the true resistance in
low frequencies, but this has not been confirmed by
later studies. In the meantime, reference values estab-
lished for the IOS method of FOT are needed as the
IOS system is currently used in clinical research and
practice at many centers. Table 1 summarizes a com-
parison of different FOT techniques.
We have performed FOT measurements using the
IOS. The aim of our study was to present reference
values for average and within-breath measurements for
pulmonary impedance measurements in asympto-
matic elderly subjects aged >70 years.
Materials and Methods
Study design
In 1998/1999, a postal questionnaire study was per-
formed on the elderly population in the city of Bergen,
Norway, population approximately 209 000 at the time
(13–17). An age- and sex-stratified random sample
was drawn from all subjects aged above 69 years
(n = 25 997). The total initial sample was 2871 persons,
of which 1649 responded. The response rate fell con-
siderably with increasing age and was lower among
subjects living in nursing home than among those
living at home (14). The questionnaire concerned res-
piratory health and was based on the American Tho-
racic Society (ATS)/Division of Lung Disease (DLD)
respiratory questionnaire (18). An age- and sex-
stratified sample of 319 subjects was drawn from the
healthy responders to undergo PFTs and blood gas
analyses. Exclusion criteria were chronic or current
acute respiratory disease, ATS/DLD dyspnea grade 4
(after walking 100 m on level ground), heart disease or
hypertension if complicated by ATS/DLD dyspnea
grade 3 (ever having to stop because of breathlessness
on the level), or current-smoker status. Ex-smokers
were included, and their smoking history was noted.
Never-smokers were defined as those who had smoked
less than 20 packs/lifetime or less than 1 cigarette/day
for 1 year. PFTs were performed in the department.
Out of the 161 participants who showed up at the test
site to perform PFTs, 148 test subjects performed IOS
measurements. Spirometry and blood gas sampling
Table 1. Different methods of the forced oscillation technique
Method Frequency Applied pressure Signal Advantage of technique
Monofrequent Single Continuous Sinusoidal Simple calculation
Pseudorandom Multiple Continuous Generated signal Yields more information
Impulse oscillometry system Multiple Short impulses Squared electrical signal Better time resolution
Pulmonary impedance in asymptomatic elderly Aarli et al.
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was also performed, and the results have been pub-
lished previously (16, 17).
Measurements
The FOT measurements were performed on a
Masterscreen IOS (version 4.5; Erich Jaeger Gmbh,
Würzburg, Germany). Each patient performed 2–5
measurements while seated and wearing a nose clip.
Each measurement lasted 30 s of resting tidal breath-
ing. A cylindrical cardboard mouthpiece was used with
the subject firmly supporting their cheeks with their
hands. The IOS pneumotachometer was calibrated
with a 2-L syringe, and in addition, quality control was
performed against a reference impedance of 0.2 kPa/
L/s at the beginning of each day and after 4 h of use.
The 148 test subjects performed a total of 334 indi-
vidual FOT measurements. Only one test subject was
unable to perform the test because of an anxiety attack.
Two test subjects had to be excluded due to incomplete
data. The measurement acceptance criteria proposed
by the ERS task force in 2003 states that tests are to be
discarded if there is sign of swallowing, glottis closure,
leak around the mouthpiece, improper seal with the
noseclip, irregular breathing or hyperventilation (10).
The primary data were reviewed, and individual meas-
urements were excluded if there were signs of leakage
on the volume graph, downward drift for inspiratory
leaks and upward drift for expiratory leaks (n = 4), if
the patient hyperventilated as defined as breathing
faster than 25 breaths per minute (n = 20) and if there
were large spikes on the impedance 5 Hz tracing (Z5)
believed to be caused by glottis movement or swallow-
ing (n = 24). Only measurements from subjects with at
least two technically valid tests were included. Alto-
gether, 117 test subjects performed at least two FOT
measurements that met the acceptance criteria.
Spirometry
Spirometry was performed with a Vitalograph dry
wedge bellows. The spirometer was calibrated at the
beginning of each day using a 1-L syringe with
repeated strokes up to 9 L. Measurements were per-
formed and reported according to ATS guidelines. Dif-
ficulties in test cooperation resulted in only 119 of the
total original 161 participants having completed spiro-
metric tests by ATS criteria. The most common reasons
for not being able to perform spirometry were cough-
ing within the first second, too early termination,
leakage and not being able to follow instructions. The
participants with valid spirometry measurements were
not identical with those who were able to perform FOT
measurements on the IOS. Of the 117 participants with
acceptable FOT measurements, 95 had acceptable
spirometric measurements (19). We excluded test sub-
jects with pathology in the spirometry results, defined
as having a forced expiratory volume in 1 s (FEV1) or
forced vital capacity (FVC) of less than 80% of pre-
dicted or having a FEV1/FVC ratio less than the 5
percentile (16). Altogether, 75 subjects had both a
normal and acceptable spirometry and acceptable FOT
measurements by these criteria.
Statistical analysis
Statistical Package for Social Sciences (SPSS) software
version 18.0 (SPSS Inc., Chicago, IL, USA) was used for
data management and analysis. The impedance param-
eters did not have a normal distribution but were suffi-
ciently normalized using natural log transformation.
Parameter mean was back-transformed from geometric
mean, while the 95th percentile [or 5th percentile in the
case of reactance at 5 Hz (X5)] was established empiri-
cally and reported for whole-breath, inspiratory and
expiratory values for resistance at 5 Hz (R5), resistance
at 20 Hz (R20), X5, resonant frequency (fres) and area
of reactance (AX), the area between the reactance zero
axis, and the negative values of reactance at all frequen-
cies from 5 Hz to the fres. Thus, the AX is an integration
of the fres and the frequency dependency of the reac-
tance. In effect, it functions to amplify the signal of
reactance at lower frequencies. The within-breath
X5 difference was estimated as mean inspiratory
X5 - mean expiratory X5 = difference between inspira-
tory and expiratory X5 (DX5). Repeatability of the
parameters was calculated from the raw data and is
reported as mean individual coefficient of variation
(CV). On the transformed data, multiple linear regres-
sion was performed using the enter method where
dependent variables for the impedance data were
entered separately along with the independent variables
of height and weight. Predictive equations were gener-
ated for men and women for the mean of all whole-
breath FOT parameters, as well as separately for the
mean of all inspiratory and expiratory measurements
(Table 2). To estimate the upper and lower limits of
normal, the standard deviation (SD) of residuals
was calculated as SD (actual value - predicted
value) = residual SD (RSD). As we are only interested in
pathology resulting in high resistances, AX or fres, the
upper limit of normal can thus be estimated as
predicted + 1.65 ¥ RSD. Conversely, for X5, where we
are interested in pathology resulting in low X5, the
lower limit of normal can be estimated as pre-
dicted - 1.65 RSD. Wilcoxon–Mann–Whitney test was
Aarli et al. Pulmonary impedance in asymptomatic elderly
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performed to examine group differences between men/
women and smokers/ex-smokers.
Results
The 75 subjects in the study ranged from 70 to 98 years
of age, with a mean age of 79 (Table 3). There were 11
male ex-smokers (28%) with an average estimated
smoking burden of 20 pack years (20 cigarettes/day/
year) and 16 female ex-smokers (46%) with an average
of 4 pack years. In women, mean FEV1 was 1.88 L,
mean FVC was 2.56 L, and mean FEV1/FVC ratio was
<73.4%. For men, mean FEV1 was 2.82 L, mean was
FVC 3.89, and mean FEV1/FVC ratio was <72.4%
(Table 3). The subjects who failed to produce accept-
able measurements were similar in age, height and
weight, and there was no sex difference. They had a
nonsignificant higher smoking burden and poorer
spirometry results (data not shown).
FOT
Table 4 summarizes the impedance measurements in
men and women. In women, resistance measures were
higher, and reactance measures lower than in men. For
the other parameters, we did not find significant dif-
ferences between the sexes. The mean was not affected
by smoking history. As a measure of repeatability, we
have listed the mean individual CV for the different
parameters. Acceptable CVs according to the ERS task
force, ranging 5%–15%, were found for R5, R20 and
fres, while the CV was poorer for X5 and AX (10). As
shown in Fig. 1, the variation shows some dependency
on the magnitude of the measurements. Repeatability
was poorer with higher resistance measurements and
Table 2. Predictive equations for impedance parameters in asymptomatic elderly
Men n = 40 R2 RSD Women n = 35 R2 RSD
Ln R5 3.02 - 0.023H 0.19 0.056 Ln R5 2.68 - 0.026H + 0.012W 0.30 0.047
Insp 2.37 - 0.020H 0.17 0.043 Insp 2.49 - 0.025H + 0.011W 0.29 0.039
Exp 3.62 - 0.026H 0.17 0.080 Exp 2.75 - 0.026H + 0.013W 0.26 0.069
Ln R20 1.52 - 0.016H 0.12 0.041 Ln R20 1.26 - 0.017H + 0.009W 0.25 0.031
Insp 1.43 - 0.016H 0.14 0.034 Insp 0.96 - 0.015H + 0.007W 0.18 0.027
Exp 1.42 - 0.015H 0.09 0.049 Exp 1.49 - 0.019H + 0.010W 0.27 0.035
Ln (–X5) 3.57 - 0.033H 0.19 0.023 Ln (–X5) 3.85 - 0.041H + 0.014W 0.31 0.027
Insp 1.64 - 0.022H 0.13 0.026 Insp 4.23 - 0.043H + 0.013W 0.45 0.024
Exp 5.91 - 0.047H 0.20 0.034 Exp 1.12 - 0.019H* 0.03 0.043
Ln AX 12.0 - 0.074H 0.22 0.19 Ln AX 10.8 - 0.074H 0.21 0.46
Insp 8.4 - 0.054H 0.21 0.15 Insp 10.7 - 0.069H 0.32 0.37
Exp 15.1 - 0.030H 0.20 0.33 Exp 9.06 - 0.059H* 0.08 0.77
Ln fres 6.72 - 0.023H 0.18 1.8 Ln fres 7.12 - 0.027H 0.22 2.4
Insp 6.50 - 0.022H 0.22 1.5 Insp 7.08 - 0.027H 0.29 1.9
Exp 7.35 - 0.026H 0.16 2.2 Exp 6.71 - 0.024H 0.13 2.6
Impedance parameters were normalized for computation of multivariate linear regression. Antilog of the result of the equations will give individual’s
predicted value. The 95th percentile for R5, R20, AX and fres can thus be calculated by adding, and the 5th percentile for X5 by subtracting 1.65 ¥ RSD
to the predicted value.
*Not significant contribution of height to equation, P > 0.05.
Ln, natural log; insp, ln of the inspiratory value; exp, ln of the expiratory value; H, height (cm); W, weight (kg); RSD, residual standard deviation;
R2, variability; AX, area of reactance; R5, resistance at 5 Hz; R20, resistance at 20 Hz; X5, reactance at 5 Hz; fres, resonant frequency.
Table 3. Anthropometric data and pulmonary function tests
Men Women
Subject (n) 40 35





Height (cm) 173  6 159  6
Weight (kg) 76.4  12.7 65.5  10.8
BMI (kg/m2) 25.3  3.5 25.9  3.9
Spirometry
FEV1 (L) 2.82  0.62 1.88  0.48
FEV1 % predicted* 102 110
FVC (L) 3.89  0.77 2.56  0.65
FEV1/FVC (%) 72.4  5.6 73.4  6.4
Ex-smokers 11(28%) 16(46%)
Pack years 20 4
Data presented as mean  standard deviation.
*Reference values by Hardie et al. (16).
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity.
Pulmonary impedance in asymptomatic elderly Aarli et al.
4 The Clinical Respiratory Journal (2012) • ISSN 1752-6981
© 2012 Blackwell Publishing Ltd
lower reactance. Repeatability was very similar for R5
and R20. There was evidence of frequency dependence,
as mean R5 was approximately 0.08–0.11 kPa/L/min
higher than mean R20.
DX5 is presented in Table 4 and as a function of the
FEV1/FVC ratio in Fig. 2. The mean difference was
close to zero for both men and women. The mean for
ex-smokers and never-smokers was 0.02 and 0.03,
respectively. Only one subject had a DX5 over
0.28 kPa/L/s, which has been established as the thresh-
old representing EFL (Fig. 2) (2, 8, 9). No obvious asso-
ciation was found between DX5 and FEV1/FVC.
Predictive equations for the impedance parameters








R5 (kPa/L/s) 0.37 (.65) 0.50 (0.85) 10
Inspiration 0.33 (0.60) 0.45 (0.73) 10
Expiration 0.40 (0.78) 0.55 (0.96) 13
R20 (kPa/L/s) 0.29 (0.56) 0.39 (0.59) 11
Inspiration 0.27 (0.50) 0.36 (0.53) 10
Expiration 0.31 (0.59) 0.42 (0.63) 12
X5 (kPa/L/s) -0.11 (-0.28) -0.17 (-0.31) 18
Inspiration -0.12 (-0.19) -0.18 (-0.30) 19
Expiration -0.11 (-0.45) -0.15 (-0.39) 25
DX5 (kPa/L/s)* 0.02 (0.26) 0.00 (0.24)
AX (kPa/L) 0.45 (1.96) 0.80 (3.04) 26
Inspiration 0.41 (1.11) 0.75 (2.66) 23
Expiration 0.48 (4.35) 0.78 (4.47) 34
fres (Hz) 15.3 (26.4) 17.0 (28.6) 10
Inspiration 14.5 (24.9) 16.2 (28.0) 9
Expiration 15.8 (28.3) 17.5 (32.0) 13
Values presented as mean derived from back-transformation of the
geometric mean (95th percentile of the residual).
*DX5 is derived from the raw data.
CV, mean individual coefficient of variation, DX5, difference between
inspiratory and expiratory X5; AX, area of reactance; R5, resistance at
5 Hz; R20, resistance at 20 Hz; X5, reactance at 5 Hz; fres, resonant
frequency.
Fig. 1. (A) The difference between two resistance at 5 Hz (R5) measurements drawn against the average of the two tests
demonstrating increasing variation at higher resistance measurements. (B) The difference between two reactance at 5 Hz (X5)
measurements drawn against average showing increasing variation at lower reactance measurements.
Fig. 2. The difference between reactance at 5 Hz (X5) inspira-
tion and X5 expiration (DX5) compared with the forced expira-
tory volume in 1 s/forced vital capacity (FEV1/FVC). The
reference line is set at 0.28 kPa/L/s.
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were generated for men and women, and are listed in
Table 2. Height was the best predictor for all respira-
tory impedance parameters. For X5 expiration and AX
expiration in women, the contribution of height to the
reported equation was found insignificant (P > 0.05).
Weight only significantly improved the multivariate
linear regression in women for the resistance param-
eters as well as whole-breath and inspiratory X5
(P < 0.05). Contribution of age was negligible.
Discussion
We present predictive equations separated by sex for
whole-breath and within-breath impedance param-
eters in asymptomatic elderly based on height and
weight. We found considerable frequency dependence,
with a significantly higher R5 than R20. The mean DX5
in this reference sample was close to zero, and only one
subject showed evidence of flow limitation.
For comparison, Table 5 demonstrates the resistance
values according to this study compared with three
previous studies. The Viasys health-care equations are
the normal values supplied by the IOS software. The
study population for these equations did not include
elderly >70 years, and values reported by the software
are extrapolated from predictive equations for
younger age groups (20). The study by Guo et al. is
the only other study presenting reference values for
FOT in the elderly (11). Our study yields higher resist-
ance values than what was found by Guo et al., which
excluded smokers and test subjects with less than
super-normal spirometry. Mean FEV1 in the study
was 104% of predicted for men and 111% of pre-
dicted for women, and for FEV1/FVC ratio, 114% and
108% of predicted, respectively. This would seemingly
select a subgroup of elderly with superior lung func-
tion. In our sample, we had a large number of
ex-smokers; some of them with a considerable
smoking history. Because the IOS did not clearly sepa-
rate the never-smokers from the ex-smokers, we have
kept all in the sample. Previous studies on the same
study population also failed to show any significant
effect of previous smoking history on arterial blood
gasses and only a small effect on FEV1 (17). Retaining
the ex-smokers in the reference sample was based on a
desire to avoid a super-healthy selection bias specifi-
cally in the elderly where almost all men (and a sig-
nificant proportion of the women) have smoked
sometime during their lifetime. We believe that refer-
ence values should depict realistic expectations repre-
sentative for the generally healthy population.
Pasker et al. is the largest FOT reference value study
performed among adults and elderly but contains few
elderly over 70 years (21). Both Pasker et al. and Guo
et al. performed FOT measurements using PRN FOT,
while our study used the IOS method. These studies
report mean resistance (Rm) at frequencies between 6
and 24 Hz (21), and between 4 and 16 Hz (11). Clearly,
R5 is not identical to Rm, but in the study of Guo et al.,
there was virtually no frequency dependence of resist-
ance, and in the study of Pasker et al., the frequency
dependence was very small.
Ideally, the true pulmonary impedance should be
reported regardless of method. However, differences
have been shown between these different methods
where the resistance values measured with IOS tended
to be significantly higher than those measured with
PRN FOT, especially at low frequencies and high resist-
ances (12). In a comparison study by Hellinckx et al.,
the authors were able to show in a mechanical struc-
ture model that the PRN method gave resistance
results in closer agreement to the wave-tube technique
than was the case for IOS (12, 22). In this study, reac-
tance values and fres from PRN and IOS methods were
very similar. Still, this was in a mechanical model, and
which of the PRN or IOS methods gives the truest
values for resistance in the human remains to be
shown. In the meantime it is important to be aware of
these differences and to apply reference values appro-
priate to the method in use.
In the present study, only one test subject had a
within-breath reactance, DX5 crossing the threshold
proposed by Dellaca et al. of 0.28 kPa/L/s (9). The
importance of this finding is that few elderly without
respiratory complaints would be labeled expiratory
flow limited using this method if the same threshold is
applicable for the IOS. We believe that the Dellaca
method for measuring EFL is an important future
application of the FOT, as it is simple to perform and
gives information concerning a very central aspect of
the pathophysiological background for dypsnea in
Table 5. Resistance value according to predictive equations
from this study and three previous studies
Reference Men n Women n
R5 R5
Present study 0.37 40 0.51 35
Viasys health care 0.32 298 0.43 208
Rm Rm
Guo et al 0.22 77 0.28 146
Pasker et al 0.24 137 0.30 140
Values are in kPa/L/s, and are those given for men: height 174 cm,
weight 77 kg, age 80 years; and for women: height 160 cm, weight
67 kg, age 80 years.
Rm, mean resistance; R5, resistance at 5 Hz.
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COPD patients (23). Reference data on the DX5 will
aid in interpretation of these results in patients.
As presented in Fig. 2, it is interesting to note that
there is no sign of EFL in these elderly persons without
respiratory symptoms, even if several show FEV1/FVC
ratios less than 0.7. This is in contrast with what one
might have expected if these persons were to have been
diagnosed by Global Initiative for Chronic Obstructive
Lung Disease criteria as COPD patients. This finding is
yet another piece of evidence that FEV1/FVC ratios
between 0.6 and 0.7 need not be indication of patho-
logic airways and should not be defined as such based
on the arbitrary cut point of 0.7 (24). The DX5 method
measures flow limitation at tidal-volume breathing
that is not identical to flow limitation during forced
expiration; a low FEV1/FVC ratio alone does not imply
EFL or a high DX5.
The most obvious limitation to the present study is
the small sample size that increases the risk of statisti-
cally significant differences being false-positive, risk of
real differences being falsely negative and it makes the
reference equations less stable. In addition, there could
be a selection bias in that subjects with superior health
from the postal questionnaire study probably would be
more likely to participate in the clinical study. In
absence of other reference value, studies performed on
elderly using the IOS our equations will form a rel-
evant reference for clinical evaluation in the elderly.
The study sample is well characterized from previous
publications (16, 17). However, future larger studies
for establishing more robust equations for IOS are still
needed. Other limitations are that most test subjects
only had two valid FOT measurements and the
intersession test repeatability of the measurements was
somewhat poorer than in previous studies. This is
partly explained by the fact that the variation seems to
depend on the magnitude of the measurements, and
we found higher resistance measurements and lower
reactance measurements than in the other studies. We
speculate that variability may generally be higher in the
elderly and that the use of a tongue positioner instead
of a circular cardboard mouthpiece could have
improved the measurements. The repeatability was for
the most part acceptable for the resistance measure-
ments (CV 10%–12%) and for fres (CV 9%–13%). For
comparison, Guo et al. had a mean CV of 6% for Rm
and fres. CV for these parameters were within the
limits of the short-term intraindividual CV of FOT
indices in healthy adults reported by the ERS task force
(range 5–15%), but the repeatability of X5 and AX
were poorer (10). It could be argued that CV is unsuit-
able to estimate variability for most of the reactance
parameters, as these values commonly are close to zero.
Instead, it has been suggested calculating the absolute
difference values of the reactance parameters (1). By
this method, we can point out that the 95th percentile
of the difference between first and second test for X5
was approximately 0.13 kPa/L/s, whereas for R5, the
95th percentile of difference was approximately
0.25 kPa/L/s (Fig. 1). This also illustrates why using the
CV as a measure of repeatability for X5 may not be
appropriate.
This study presents the first reference values for
average and within-breath impedance measurements
in asymptomatic elderly aged >70 years using the IOS
method. We found higher resistance measurements
than what is reported in previous studies and signifi-
cantly larger frequency dependence (11, 20, 21). Using
the threshold proposed by Dellaca et al. on DX5, only
one of our elderly test subjects would be labeled EFL
(8, 9).
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Background: Tidal expiratory flow limitation (EFL
T
) is frequently found in patients with
COPD and can be detected by forced oscillations when within-breath reactance of a single-
breath is 0.28 kPa s L 1. The present study explored the association of within-breath reactance
measured over multiple breaths and EFL
T
 with 6-minute walk distance (6MWD), exacerbations,
and mortality.
Methods: In 425 patients, spirometry and forced oscillation technique measurements were
obtained on eight occasions over 3 years. 6MWD was assessed at baseline and at the 3-year 
visit. Respiratory symptoms, exacerbations, and hospitalizations were recorded. A total of 5-year 
mortality statistics were retrieved retrospectively. We grouped patients according to the mean 
within-breath reactance ( Xrs , measured over several breaths at baseline, calculated as mean
inspiratory–mean expiratory reactance over the sampling period. In addition to the established 
threshold of EFL
T
, an upper limit of normal (ULN) was defined using the 97.5th percentile





. Annual exacerbation rates were analyzed using a negative
binomial model in the three groups, supplemented by time to first exacerbation analysis, and 
dichotomizing patients at the ULN.
Results: In patients with COPD and baseline Xrs below the ULN (0.09 kPa s L 1), 6MWD 
was stable. 6MWD declined significantly in patients with Xrs ULN. Worse lung function 
and more exacerbations were found in patients with COPD with Xrs ULN, and patients 
with Xrs ULN had shorter time to first exacerbation and hospitalization. A significantly
higher mortality was found in patients with Xrs ULN and FEV
1
50%.
Conclusion: Patients with baseline Xrs ULN had a deterioration in exercise perfor-
mance, more exacerbations, and greater hospitalizations, and, among those with moderate 
airway obstruction, a higher mortality. Xrs is a novel independent marker of outcome in 
COPD.
Keywords: forced oscillation technique, reactance, COPD, exacerbations, 6-minute walk test,
mortality
Introduction
COPD is a major cause of morbidity and mortality, leading to an estimated 3.1 million
deaths globally in 2012.1 Although symptoms and exacerbation rate have been added 
to our assessment system of COPD,2 spirometry remains an important tool in assessing
severity and prognosis in this disease. Changes in the forced expiratory volume in 1
second (FEV
1
) are still the best indicator of disease progression and the risk of dying 
from COPD.2,3 Yet, on an individual level, FEV
1
 is an unreliable marker of morbidity,
especially in early disease,4–6 and there is a need to identify alternative objective tests
that can aid in stratifying the risk of further patient deterioration.
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Patients who exhibit tidal expiratory flow limitation 
(EFL
T
) might be such a subgroup. EFL
T
 occurs when increases 
in driving pressure fail to increase expiratory flow during 
resting tidal breathing and is most often seen in patients with 
severe COPD,7,8 although it can occur with only moderate 
airway obstruction. Previous studies of EFL
T
 in COPD have 
focused on its association with operating lung volume, exer-
cise tolerance,9,10 and its relation to breathlessness.11–13 It is 
not known whether EFL
T




 can be detected by the forced oscillation technique 
(FOT).14,15 When peripheral airways collapse on expiration, 
oscillatory pressure signals are prevented from reaching 
the alveoli. As this happens, the oscillatory compliance is 
reduced. Consequently, expiratory reactance (Xrs
exp
) becomes 
more negative than the inspiratory reactance (Xrs
insp
), lead-
ing to a within-breath reactance difference ( Xrs). In the 
absence of EFL
T
, reactance measured in inspiration and in 
expiration is almost identical. The within-breath reactance 
difference ( Xrs) cut-off of 0.28 kPa s L 1 has been defined 
and validated to identify flow-limited breaths.14,15 EFL
T
 is 
not only linked to dyspnea in COPD,11,16 but also to COPD 
exacerbations, where Xrs have been found to increase at 
the onset of COPD exacerbations and decrease when the 
exacerbation resolves.17
In this study, we used forced oscillation technique to 
define EFL
T
 in 425 patients with COPD. We hypothesized 
that the presence of EFL
T
, assessed by increased mean Xrs 
( Xrs), would relate to changes in 6MWD, the risk of COPD 
exacerbations, and, possibly, mortality. We explored these 
hypotheses using baseline Xrs as a predictor for future 
events. Patients with COPD with abnormally high Xrs, 
both above the upper limit of normal (ULN) and above the 
established threshold of EFL
T
, were investigated to determine 
whether they differed from those without evidence of tidal 
expiratory flow limitation.
Methods
Study design and patients
The current data derive from the Bergen cohort of the 
Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) study,18 with additional 
patients enrolled from our clinical catchment area. Written 
informed consent was obtained from all study subjects. 
The study was approved by the regional ethics committee, 
REK vest (REK 165.08), and performed in accordance 
with the Declaration of Helsinki and the Good Clinical 
Practice guidelines (ClinicalTrials.gov; No: NTC00292552; 
www.ClinicalTrials.gov).39
Inclusion criteria for patients with COPD were: age 
40–75 years, FEV
1
 80% predicted, FEV
1
/FVC 0.7, and 
a smoking history of 10 pack-years. Study patients were 
evaluated every 6 months for 3 years with an additional visit 
at 3 months after baseline, totaling eight visits. The American 
Thoracic Society-Division of Lung Disease (ATS-DLD-78) 
questionnaire and the modified Medical Research Council 
dyspnea scale score (mMRC) were used to record respira-
tory symptoms.19,20
Post-bronchodilator spirometry and oscillatory lung mechan-
ics during tidal breathing were performed after inhalation of 
0.4 mg salbutamol (GlaxoSmithKline, Ventolin, London, UK) 
according to American Thoracic Society/European Respiratory 
Society (ATS/ERS) international standards at each visit using 
a Jaeger MasterScope CT Impulse Oscillation System (Jaeger, 
Hoechberg, Germany).21,22 Local reference values were used 
to determine the FEV
1
% predicted.23 The FOT measurements 
were performed with the patient seated, cheeks supported, and 
wearing a nose clip. We performed three continuous measure-
ments of 30 seconds, totaling 90 seconds of tidal volume breath-
ing. Acceptability of measurements was determined using the 
ERS 2003 task force recommendations.22
Xrs reactance was averaged over the 90-second sample, 
containing several breaths, and was calculated as follows: 
Xrs mean Xrs
insp
 at 5 Hz – mean Xrs
exp
 at 5 Hz. Two 
cut-offs were investigated: the ULN defined as the 97.5th 
percentile of healthy controls in the Bergen cohort of the 
ECLIPSE study ( Xrs 0.09 kPa s L 1; Figure S1),13 and at 
the established EFL
T
 defining threshold for within-breath reac-
tance, 0.28 kPa s L 1, derived from single-breath analysis.14,15 
To illustrate the variability of our multiple-breath measure-
ment, Xrs was plotted against time in a subset of the patients 
defined EFL
T
 at baseline with complete visits (N 20).
Study outcomes
Distance walked during the 6-minute walk test (6MWT) 
was used to assess exercise performance. The 6MWT was 
supervised by a trained technician and performed in a 30-m, 
straight hospital corridor according to agreed standards at 
baseline and at the end of the study, at the 3-year visit.24
Exacerbations were defined as a worsening of respiratory 
symptoms over 2 days or more that required systemic corti-
costeroids or antibiotics, alone or in combination (“moderate 
exacerbations”), or exacerbations resulting in hospitaliza-
tion (“severe exacerbations”). Assessment of exacerbations 
was performed retrospectively by the study physician at the 
half-yearly visits, over the 3-year study period.
Mortality statistics were retrieved on August 25, 2011, 
approximately 5 years after the conclusion of the baseline 




Outcomes in COPD patients with tidal EFL
visit by checking vital status in our local patient file system, 
which is linked to the Norwegian Causes of Death Registry. 
The Causes of Death Registry includes deaths of all residents, 
regardless of whether they die in Norway or abroad, and is 
assumed to have information on 98% of all deaths.25
Statistics
IBM SPSS version 22, Stata 13.1, and R 3.2.3 GUI 1.66 were 
used for different aspects of statistical analyses. Data are 
presented as mean standard deviation, median (quartiles), 
mean (95% confidence interval), and absolute count or per-
centage. Means were compared using independent samples 
t-tests, paired samples t-tests, or Mann–Whitney U test when 
appropriate.
Patients were categorized into three groups according 




 at baseline. 
We report the change in the 6-minute walk distance in these 
three groups from baseline to the 3-year visit in notched 
boxplots. Differences in walking distance between baseline 
and the end of the study were compared using paired samples 
t-test, grouping the patients according to the Xrs and the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) grade.2
The rate of exacerbations in the three groups was analyzed 
as suggested by Keene et al using a negative binomial 
regression model, accounting for the yearly variability among 
test subjects in the exacerbation rate over the 3-year study 
period, adjusting for FEV
1
, age, sex, and a binary classifier 
identifying frequent exacerbators in the year prior to inclusion.26 
Parameter effects of the baseline explanatory variables are 
reported as annual rate ratios (RRs), 95% confidence interval 
(CI), and P-values. Moderate and severe exacerbations 
requiring hospitalization were also investigated on the basis 
of the occurrence of Xrs ULN at baseline by time to first 
event analysis. Groups were compared using a log-rank test. 
Results are displayed as 1-minus-survival plots.
Survival analysis was performed with Kaplan–Meier 
survival analysis, comparing distributions with the log-
rank test, grouping patients by the occurrence of Xrs 
ULN at baseline, and by dichotomizing FEV
1




In this population of patients with COPD, 60% were men 
and had moderate to very severe airway obstruction. Women 
were, on average, 2 years younger and had lower tobacco 
exposure (Table S1); 50% of patients with COPD had 
normal Xrs, 31% were classified as being abnormal 
with Xrs ULN EFL
T
, and 18% had Xrs above the 
threshold of EFL
T
 (Table 1). From the normal to the abnor-
mal group, lung function worsened with a decline in FEV
1
 
and FVC, and an increase in body mass index (BMI) and 
mMRC. This difference was most marked between the 
normal and EFL
T
 group. For IC, we only found a significant 
difference between the normal and the EFL
T
 group.
Table 1 Baseline characteristics in COPD patients with different levels of Xrs (N 425)
Subject characteristics Normal Abnormal EFLT
Xrs ULN ULN Xrs EFLT Xrs 0.28 kPa s L
1
Subjects (n) 213 (50%) 134 (32%) 78 (18%)
Women 40% 36% 49%
Age (years) 63 (7) 64 (7) 63 (6)
BMI kg/m2 24 (5)c,d 26 (5)c,e 28 (6)d,e
Pack-years (years) 40 (24) 43 (22) 39 (22)
Frequent exacerbators (%) 13% 20% 35%
mMRC 1.2 (0, 2)c,d 1.8 (0.25, 2)c,e 2.3 (1, 2)d,e
FEV1 (L) 1.7 (0.5)
c,d 1.3 (0.5)c,e 1.1 (0.4)d,e
FEV1 (%) 52 (11)
c,d 42 (12)c 38 (13)d
FVC (L) 3.5 (0.9)c,d 3.2 (0.8)c,e 2.8 (0.9)d,e
IC (L) 2.6 (0.8)d 2.5 (0.7) 2.3 (0.7)d
IC (%) 88 (19) 85 (20) 84 (21)
6MWD (meters) 455 (102)c,d 410 (109)c,e 363 (110)d,e
Estimated exacerbations per yeara 0.7 1.3 1.6
Deathsb 25 (12)c,d 28 (21)c 18 (23)d
Notes: Data presented as mean standard deviation unless otherwise stated. aEstimated exacerbation rate by negative binomial model. bNumber of deaths at the 5-year 
census (%). Significant differences at the 5% level are marked as cbetween normal and abnormal, dbetween normal and EFLT, and 
ebetween abnormal and EFLT. pack-years: 
packs of 20 cigarettes smoked per day years as a smoker; Frequent exacerbators: percentage with 2 exacerbations the year the prior to inclusion.
Abbreviations: ULN, upper limit of normal 0.09 kPa s L 1; EFLT, tidal expiratory flow limitation; BMI, body mass index; mMRC, modified Medical Research Council dyspnea 
scale score – mean (quartiles); FEV1, forced expiratory volume in 1 second; FEV1 (%), FEV1 percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), 
IC percentage of predicted; Xrs, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.





Xrs was not a stable measurement. Many patients 
defined as EFL
T
 at baseline fell below the EFL
T
 threshold 
during the course of the study (Figure 1). Six percent of the 
consequent Xrs measurements were found to be normal; 
23% of the patients dropped out of the study before the 
final visit, the main reason being death during the study 
period (Table 2).
Relationship of EFLT to study outcomes
Xrs was as poorly correlated with baseline 6-minute 
walking distance as FEV
1
 (Figure 2A and B). On a group 
level, 6MWD declined with increasing Xrs, being 455 m in 
the normal, 410 m in the abnormal, and 363 m in the EFL
T
 
group (Table 1). In patients who completed both the base-
line and the final visit, changes in 6MWD were compared. 
No significant change between the baseline and the final 
3-year visit was seen in the 6MWD of patients with normal 
Xrs. Patients with Xrs ULN declined by a mean of 
37 m (95% CI 15–58), P 0.001, and patients with EFL
T
 
declined by 63 m (95% CI 31–95), P 0.001 (Figure 2C). 
Grouping by GOLD grade produced similar boxplots. GOLD 
2 patients remained stable whereas a significant decline was 
seen in GOLD 3–4 grades (Figure 2D).
A total of 1,289 moderate to severe exacerbations were 
recorded throughout the study. By negative binomial 
regression, estimated annual exacerbations rates were 0.7 
in patients with normal Xrs, 1.3 in patients with COPD 
with Xrs ULN, and 1.6 in patients with EFL
T
. Annual 
exacerbation RR compared to the normal group was 1.28 for 
ULN patients and 1.30 for EFL
T
 patients (Table 3). A time 
to first exacerbation analysis was performed in patients 
with COPD with and without evidence of Xrs ULN at 
baseline. Significant differences were found in both time to 
first exacerbation (P 0.009) and in time to first hospitaliza-
tion (P 0.017; Figure 3A). Median time to first moderate or 
severe exacerbation was 76 weeks in patients with COPD 
with normal Xrs, compared with only 55 weeks in COPD 
patients with Xrs ULN at baseline (Table 4). The time 
until 25% of the patients were hospitalized was 126 weeks 
in patients with normal Xrs and 72 weeks in patients 
with Xrs ULN.
Mortality
At the 5-year census, 72 (17%) of the 425 patients with 
COPD had died. Deaths were significantly more frequent 
in patients with ULN than in patients with normal Xrs, 
but not significantly different between the ULN and the 
EFL
T
, groups (Table 1). Mortality was higher in patients with 
FEV
1
 50% (Figure 4). The difference in mortality between 
patients with Xrs in the normal range and ULN was 
driven by increased mortality in patients with FEV
1
 50% 
(Figure 4). Mortality was 17% in Xrs ULN patients with 
FEV
1
 50%, compared to 5% in patients with normal Xrs 
(P 0.001; Figure 4). Mortality in patients with Xrs ULN 
was similar to what was found in patients with COPD with 
much more advanced airway obstruction.
Discussion
Using data from the ECLIPSE study, we investigated associa-
tions between increased Xrs at the ULN and at the threshold 
of EFL
T
 with decline in 6MWD, risk of later exacerbations, 
and all-cause mortality. No change in 6MWD was found 
in patients with COPD with Xrs in the normal range. All 
patients with COPD with Xrs ULN deteriorated signifi-
cantly in 6MWD. Patients with COPD with Xrs ULN had 
increased risk for both moderate and severe exacerbations, 
and, in the patients with only moderate airway obstruction, 
FEV
1
 50%, a significantly higher mortality. This study 
Figure 1 Timeplot illustrating the variability of Xrs measurements (splines) over 
the course of the study shown in the first 20 patients with COPD with complete 
visits, defined as having EFLT at baseline ( Xrs 0.28 kPa s L
1). The dotted line is 
set at 0.09 kPa s L 1, the upper limit of normal and the solid line at EFLT.




FOT not performed at the final visit 16 4
Refused further participation 8 2
Excluded due to use of oral steroids 8 2
Excluded after being diagnosed with pulmonary cancer 5 1
Other causes 18 4
Total 96 23
Abbreviation: FOT, forced oscillation technique.
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demonstrates that Xrs provides valuable extra information 
in addition to FEV
1
 when characterizing the effects of small-
airway obstruction on key COPD outcomes.
We defined the ULN at the 97.5th percentile of healthy 
controls included in our study. Data describing the control 
group have previously been published.13,18 The FOT threshold 
identifying a single flow-limited breath has been defined 
when within-breath reactance was 0.28 kPa s L 1.14,15 
We interpreted our continuous spectrum measurements 
performed over several breaths as showing evidence of 
flow limitation when measurements between the ULN 
and the threshold of EFL
T
 were found. These borderline 
measurements are thought to represent a mixture of normal 
and flow-limited breaths.
Exercise limitation is extremely common in COPD, and 
even small decreases in the 6MWD over time identify patients 
with increased risks of dying.27 When EFL
T
 is present, 
patients can only increase their minute ventilation during 
exercise by increasing breathing frequency or by dynamic 
hyperinflation, allowing end-expiratory lung volume to 
rise.28 Dynamic hyperinflation can be induced by self-paced 
walking exercise. This is usually assessed by changes in 
Figure 2 (A) Six-minute walk distance (6MWD) in patients with COPD (N 388) at different levels of FEV1% predicted (A) and Xrs (B) at baseline. Dotted lines set at 
350 m (horizontal) and at Xrs 0.09 kPa s L 1, upper limit of normal (ULN), and Xrs 0.28 kPa s L 1, the threshold for tidal expiratory flow limitation (EFLT). The solid lines 
represent the regression lines. (C) 6MWT at baseline and the 3-year visit presented by notchplots with quartiles, 95% central range and outliers among COPD patients of 
GOLD II–IV grades and categorized according to Xrs (D) as normal (white), below EFLT, but above ULN (light gray), and EFLT threshold (gray). Non-overlapping notched 
areas are likely to represent significant differences between groups. Solid lines are drawn between the mean 6MWD at baseline and the 3-year visit.





operating lung volume.12,29 We did not measure lung volume 
during the 6MWT, but reasoned that patients with COPD 
showing evidence of flow limitation at baseline, either as 
having Xrs ULN or the threshold of EFL
T
, were more 
likely to have a worse exercise tolerance at the same visit. 
This was true on a group level. The EFL
T
 group had the 
lowest 6MWD, but neither FEV
1
 % predicted nor any cut-off 
level of Xrs could identify patients with COPD with a short 
walking distance ( 350 m), as proposed by Spruit et al.30 
No significant decline was seen in patients with Xrs in the 
normal range; in patients with COPD with Xrs ULN, 
it declined 37 m, and in patients with EFL
T
, it declined by 
63 m. The minimal clinically important difference on an 
individual level has been suggested to be 30 m in an ERS/
ATS systematic review;31 consequently, the differences seen 
over time between our subgroups defined by Xrs ULN 
and EFL
T
 are likely to be clinically important.
Exacerbation and hospitalization rates at our site were 
similar to those reported in the completed ECLIPSE study 
and in the TORCH study.32,33 By negative binomial regres-
sion, the Xrs cut-offs ULN and EFL
T
 were both signifi-
cant predictors for higher rates of exacerbations with very 
similar RR, demonstrating that the increased risk of exacer-
bations by EFL
T
 is identified already at ULN. In the time to 
first event analysis of patients with Xrs ULN, we found 
a shorter time to first exacerbation and a shorter time to first 
hospitalization than that of the COPD patients with Xrs in 
the normal range. A previous study on hospitalized patients 
showed that many, but not all, have FOT-defined EFL
T
 during 
a COPD exacerbation.17 FOT measurements performed 
during hospitalized COPD exacerbations show that Xrs 
measurements improve during resolution of an exacerba-
tion, although many patients remain EFL
T
 at discharge.17 
At present, there is a shortage of readily measurable bio-
markers that can predict the risk of future exacerbations. 
Our data suggest that, after adjusting for lung function and 
exacerbation history, EFL
T
 measurement can identify patients 
who are more likely to develop exacerbations. Further pro-
spective studies to confirm these observations and explore 
their mechanism are merited.
Patients with COPD with an FEV
1
 50% predicted and 
evidence of EFL
T
, defined as baseline Xrs ULN, had signifi-
cantly higher risk of dying within the 5-year follow-up. Similar 
associations were not found in the patients with more advanced 
Table 3 Annual rate ratios estimated by negative binomial 
regression (N 395)
Baseline explanatory variables RR 95% CI P-value
Xrs
ULN (0.09 kPa s L 1) and EFLT 1.28 1.05, 1.55 0.011
EFLT (0.28 kPa s L
1) 1.30 1.05, 1.64 0.009
FEV1 % predicted 0.07 0.04, 0.14 0.001
Age in decades 1.36 1.06, 1.34 0.009
Sex (male) 0.85 0.72, 1.00 0.048
Exacerbation in the year prior to inclusion
2 1.99 1.64, 2.41 0.001
Intercept 0.98 0.42, 2.27 0.965
Abbreviations: RR, estimated rate ratio; 95% CI, confidence interval; ULN, upper 
limit of normal 0.09 kPa s L 1; EFLT, tidal expiratory flow limitation; FEV1, forced 
expiratory volume in 1 second; FEV1 (%), FEV1 percentage of predicted.
Figure 3 Time to first moderate or severe exacerbation (A) and to the first hospitalization (B) in COPD patients with Xrs measurements above the upper limit of normal 
(ULN), 0.9 kPa s L 1 (solid line), and below the ULN at the baseline visit. Dashed line at 25%.
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airway obstruction and FEV
1
 50%. However, COPD is a 
complex, heterogeneous disease, and respiratory impairment 
is associated with higher incidence of comorbidities, such as 
hypertension, cardiovascular disease, and diabetes.34 If there 
is an association between Xrs and mortality, the higher risk 
of adverse outcomes associated with comorbid disease could 
mask such an association with advanced disease. Although the 
association between death and Xrs was highly significant, 
this sub-analysis should be interpreted with caution due to the 




There are certain limitations of this study. The FOT 
threshold identifying a single flow-limited breath has been 
defined at Xrs 0.28 kPa s L 1.14,15 It is not known whether 
the use of this threshold may lead to different results when 
applied to values measured over a continuous spectrum of 
several breaths. Previously published data show that the 
end-expiratory lung volume varies from breath-to-breath, 
affecting the prevalence of EFL
T
.8,15 Although the prevalence 
of EFL
T
 increased as the FEV
1
% predicted declined, not all 
patients with very severe airway obstruction were found to 
have EFL
T
. In previous studies on elderly and COPD with 
the NEP technique, higher prevalence of EFL
T
 have been 
reported than in the present study.11,35,36 Different inclusion 
criteria and differences in sensitivity between the NEP and 
the FOT technique, together with the possibility that in 
borderline patients the application of a NEP per se could 
lead to development of EFL
T
, are likely explanations. The 
wide reference range of FEV
1
 inevitably may also lead to 
an overestimation of the suspected lung function decline in 
many patients.23
As previously noted, EFL
T
 varies between breaths in 
many patients with COPD and varies with repeat testing, 
likely reflecting differences in the end-expiratory lung 
volume on different test days.13 Physiological variability in 
these measurements might require the repetition of this test 
in different periods to increase the sensitivity of our test. 
Despite this limitation, important relationships related to 
the presence of tidal flow limitation were seen, even when 
the data were controlled for severity of airflow obstruction 
measured by FEV
1
. The data reflect results from the largest 
recruiting center in the ECLIPSE study, in which patients 
were carefully characterized using standardized methodolo-
gies including oscillatory mechanics.18,37
Conclusion
Consistent differences in clinically relevant outcomes were 
found, such as exercise capability, exacerbations, hospitaliza-
tions, and death in COPD patients with baseline Xrs beyond 
the ULN. This is below the established threshold for EFL
T
. 
Our data support previous studies showing that patients with 
EFL
T
 have worse lung mechanics than is evident from FEV
1
 
measurement alone.11,38 The present study suggests that 
evidence of EFL
T
, measured during tidal breathing in an 
effort-independent fashion, can identify a subgroup of COPD 
patients with worse clinical outcomes.
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Time (weeks) until 25% of the 
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Log-rank test P 0.017
N dead at 5-year follow-up 25 (12%) 46 (22%)
Log-rank test P 0.011
Note: ULN defined at Xrs 0.09 kPa s L 1.
Abbreviations: ULN, upper limit of normal 0.09 kPa s L 1; 95% CI, 95% confidence 
interval.
Figure 4 Kaplan–Meier survival curves in COPD patients with normal Xrs and in 
COPD patients with Xrs measurements above the upper limit of normal (ULN). 
Test of equality of survival distributions was performed using log-rank test.
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Table S1 Baseline characteristics in men and women (N 425)
Subject characteristics Total Men Women P-value
Subjects (n) 425 254 171
Age (years) 63 (7) 64 (7) 62 (7) 0.014
BMI kg/m2 25 (5) 26 (5) 25 (6) ns
Pack-years (years) 41 (23) 45 (24) 33 (18) 0.001
mMRC 1.6 (1, 2) 1.6 (1, 2) 1.7 (1, 2) ns
FEV1 (L) 1.5 (0.5) 1.6 (0.6) 1.3 (0.4) 0.001
FEV1 (%) 46 (14) 45 (14) 48 (13) 0.007
FVC (L) 3.3 (0.9) 3.7 (0.8) 2.6 (0.6) 0.001
Xrs (kPa s L 1) 0.14 (0.17) 0.13 (0.14) 0.16 (0.20) ns
Note: Data presented as mean (standard deviation) unless otherwise stated.
Abbreviations: ULN, upper limit of normal 0.09 kPa s L 1; EFLT, tidal expiratory flow limitation; BMI, body mass index; Pack-years, packs of 20 cigarettes smoked per day 
years as a smoker; Frequent exacerbators, percentage with 2 exacerbations the year the prior to inclusion; mMRC, modified Medical Research Council dyspnea scale 
score – mean (quartiles); FEV1, forced expiratory volume in 1 second; FEV1 (%), FEV1 percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC 
percentage of predicted; Xrs, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.
Figure S1 Scatterplot of Xrs plotted against FEV1 % predicted in healthy controls (N 229). Mean represented by the solid line. The dashed line represents the 97.5th 
percentile, the upper limit of normal (ULN).
